CN112451649A - Pharmaceutical composition for preventing and treating myopia and/or asthenopia and preparation thereof - Google Patents
Pharmaceutical composition for preventing and treating myopia and/or asthenopia and preparation thereof Download PDFInfo
- Publication number
- CN112451649A CN112451649A CN202011494953.XA CN202011494953A CN112451649A CN 112451649 A CN112451649 A CN 112451649A CN 202011494953 A CN202011494953 A CN 202011494953A CN 112451649 A CN112451649 A CN 112451649A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- semen
- asthenopia
- myopia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004379 myopia Effects 0.000 title claims abstract description 61
- 208000001491 myopia Diseases 0.000 title claims abstract description 61
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 57
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 82
- 210000000582 semen Anatomy 0.000 claims abstract description 75
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 29
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 29
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 29
- 229940082787 spirulina Drugs 0.000 claims abstract description 28
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 27
- 235000008434 ginseng Nutrition 0.000 claims abstract description 27
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 26
- 210000002826 placenta Anatomy 0.000 claims abstract description 26
- 241000222336 Ganoderma Species 0.000 claims abstract description 24
- 239000000463 material Substances 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 18
- 240000000249 Morus alba Species 0.000 claims abstract description 18
- 241000237502 Ostreidae Species 0.000 claims abstract description 18
- 241000123113 Phellinus igniarius Species 0.000 claims abstract description 18
- 235000020636 oyster Nutrition 0.000 claims abstract description 18
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 17
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 17
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 17
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 17
- 235000008397 ginger Nutrition 0.000 claims abstract description 17
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 16
- 241000931705 Cicada Species 0.000 claims abstract description 16
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 16
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 16
- 235000006533 astragalus Nutrition 0.000 claims abstract description 16
- 235000009165 saligot Nutrition 0.000 claims abstract description 16
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 15
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract description 15
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 15
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 15
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 15
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 14
- 241000132585 Centaurea calcitrapa Species 0.000 claims abstract description 13
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 12
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 12
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 7
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 5
- 241000675108 Citrus tangerina Species 0.000 claims abstract 5
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- 239000000843 powder Substances 0.000 claims description 52
- 239000002775 capsule Substances 0.000 claims description 47
- 238000002156 mixing Methods 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 32
- 238000001914 filtration Methods 0.000 claims description 31
- 239000003826 tablet Substances 0.000 claims description 26
- 238000001035 drying Methods 0.000 claims description 24
- 241000628997 Flos Species 0.000 claims description 22
- 238000002791 soaking Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 238000000227 grinding Methods 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 241000001727 Tropicoporus linteus Species 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 12
- 235000011477 liquorice Nutrition 0.000 claims description 12
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 11
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 11
- 229940116229 borneol Drugs 0.000 claims description 11
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 11
- 239000006072 paste Substances 0.000 claims description 11
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 241000229143 Hippophae Species 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 7
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 7
- 235000003935 Hippophae Nutrition 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- 229940041616 menthol Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 230000005484 gravity Effects 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000010409 thin film Substances 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims 6
- 239000011505 plaster Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 48
- 230000008901 benefit Effects 0.000 abstract description 5
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 123
- 210000001508 eye Anatomy 0.000 description 83
- 239000008280 blood Substances 0.000 description 75
- 210000004369 blood Anatomy 0.000 description 73
- 210000003734 kidney Anatomy 0.000 description 52
- 230000007812 deficiency Effects 0.000 description 45
- 230000004438 eyesight Effects 0.000 description 41
- 230000036407 pain Effects 0.000 description 41
- 208000002193 Pain Diseases 0.000 description 40
- 210000002216 heart Anatomy 0.000 description 36
- 210000004072 lung Anatomy 0.000 description 35
- 235000009508 confectionery Nutrition 0.000 description 32
- 230000006870 function Effects 0.000 description 32
- 230000001737 promoting effect Effects 0.000 description 32
- 210000000952 spleen Anatomy 0.000 description 31
- 208000024891 symptom Diseases 0.000 description 31
- 229940079593 drug Drugs 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- 230000017531 blood circulation Effects 0.000 description 24
- 230000008961 swelling Effects 0.000 description 21
- 240000004371 Panax ginseng Species 0.000 description 20
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 18
- 239000000796 flavoring agent Substances 0.000 description 18
- 235000019634 flavors Nutrition 0.000 description 18
- 206010011224 Cough Diseases 0.000 description 17
- 206010042674 Swelling Diseases 0.000 description 17
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 16
- 239000011521 glass Substances 0.000 description 16
- 206010022437 insomnia Diseases 0.000 description 16
- 241000475481 Nebula Species 0.000 description 15
- 206010019233 Headaches Diseases 0.000 description 14
- 230000009471 action Effects 0.000 description 14
- 231100000869 headache Toxicity 0.000 description 14
- 206010062717 Increased upper airway secretion Diseases 0.000 description 13
- 206010033557 Palpitations Diseases 0.000 description 13
- 206010047513 Vision blurred Diseases 0.000 description 13
- 235000021152 breakfast Nutrition 0.000 description 13
- 208000026435 phlegm Diseases 0.000 description 13
- 241001570521 Lonicera periclymenum Species 0.000 description 12
- 208000012886 Vertigo Diseases 0.000 description 12
- 244000132619 red sage Species 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 231100000889 vertigo Toxicity 0.000 description 12
- 241001672694 Citrus reticulata Species 0.000 description 11
- 206010013774 Dry eye Diseases 0.000 description 11
- 241000234314 Zingiber Species 0.000 description 10
- 206010003549 asthenia Diseases 0.000 description 10
- 210000000038 chest Anatomy 0.000 description 10
- 231100000331 toxic Toxicity 0.000 description 10
- 230000002588 toxic effect Effects 0.000 description 10
- 230000002936 tranquilizing effect Effects 0.000 description 10
- 206010007247 Carbuncle Diseases 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 9
- 201000007100 Pharyngitis Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000001914 calming effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 8
- 240000008397 Ganoderma lucidum Species 0.000 description 8
- 206010023644 Lacrimation increased Diseases 0.000 description 8
- 206010068319 Oropharyngeal pain Diseases 0.000 description 8
- 208000001431 Psychomotor Agitation Diseases 0.000 description 8
- 206010038743 Restlessness Diseases 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000004317 lacrimation Effects 0.000 description 8
- 201000009240 nasopharyngitis Diseases 0.000 description 8
- 238000002559 palpation Methods 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 206010015958 Eye pain Diseases 0.000 description 7
- 208000005392 Spasm Diseases 0.000 description 7
- 210000000232 gallbladder Anatomy 0.000 description 7
- 235000008216 herbs Nutrition 0.000 description 7
- 208000013403 hyperactivity Diseases 0.000 description 7
- 230000004377 improving vision Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000027939 micturition Effects 0.000 description 7
- 239000004745 nonwoven fabric Substances 0.000 description 7
- 206010000077 Abdominal mass Diseases 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 6
- 206010015967 Eye swelling Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 208000009205 Tinnitus Diseases 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000004342 moderate myopia Effects 0.000 description 6
- 230000002633 protecting effect Effects 0.000 description 6
- 230000004436 pseudomyopia Effects 0.000 description 6
- 210000000115 thoracic cavity Anatomy 0.000 description 6
- 231100000886 tinnitus Toxicity 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 208000031971 Yin Deficiency Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 208000022531 anorexia Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 208000030533 eye disease Diseases 0.000 description 5
- 201000001881 impotence Diseases 0.000 description 5
- -1 liquid paraffin Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 4
- 206010010726 Conjunctival oedema Diseases 0.000 description 4
- 244000247747 Coptis groenlandica Species 0.000 description 4
- 235000002991 Coptis groenlandica Nutrition 0.000 description 4
- 240000007371 Cuscuta campestris Species 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 241000237890 Haliotis Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010041497 Spermatorrhoea Diseases 0.000 description 4
- 229940107666 astragalus root Drugs 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 206010034960 Photophobia Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 241000159213 Zygophyllaceae Species 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 2
- 241000548230 Crassostrea angulata Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 206010049077 Hernia pain Diseases 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 235000003805 Musa ABB Group Nutrition 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- 241001523579 Ostrea Species 0.000 description 2
- 108010053210 Phycocyanin Proteins 0.000 description 2
- 241001499733 Plantago asiatica Species 0.000 description 2
- 244000010922 Plantago major Species 0.000 description 2
- 235000015266 Plantago major Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010038084 Rectocele Diseases 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241001521901 Tribulus lanuginosus Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002389 essential drug Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 230000024121 nodulation Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241001313857 Bletilla striata Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 235000014552 Cassia tora Nutrition 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 206010009185 Ciliary muscle spasm Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000037803 Coptis deltoidea Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 241001522252 Crassostrea rivularis Species 0.000 description 1
- 241000382825 Cristaria plicata Species 0.000 description 1
- 241001000583 Cryptotympana atrata Species 0.000 description 1
- 244000013539 Cuscuta australis Species 0.000 description 1
- 241000110637 Cuscuta chinensis Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 208000009847 Eye Foreign Bodies Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241001489091 Ganoderma sinense Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 241000143510 Haliotis discus hannai Species 0.000 description 1
- 241001489138 Haliotis diversicolor Species 0.000 description 1
- 241001489140 Haliotis laevigata Species 0.000 description 1
- 206010019194 Head discomfort Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 241000382840 Hyriopsis cumingii Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 235000001878 Mentha haplocalyx Nutrition 0.000 description 1
- 244000280293 Mentha haplocalyx Species 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000819999 Nymphes Species 0.000 description 1
- 241000813872 Oscillatoriaceae Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000961970 Plantago depressa Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 241000879903 Pteria Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- FVECELJHCSPHKY-WTFKENEKSA-N Veratrine (amorphous) Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@]2(O)O[C@@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-WTFKENEKSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000002604 borneol group Chemical group 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- UWGBIKPRXRSRNM-UHFFFAOYSA-N cevadine Natural products CC=C(C)/C(=O)OC1CCC2(C)C3CCC4C5(O)CC(O)C6(O)C(CN7CC(C)CCC7C6(C)O)C5(O)CC24OCC13O UWGBIKPRXRSRNM-UHFFFAOYSA-N 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002445 liver protective agent Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 206010026820 marasmus Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- DJOJDHGQRNZXQQ-AWEZNQCLSA-N sakuranetin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=C(O)C=C1 DJOJDHGQRNZXQQ-AWEZNQCLSA-N 0.000 description 1
- RNAPFFYGJWALAQ-UHFFFAOYSA-N sakuranetin Natural products O1C2=CC(C)=CC(O)=C2C(=O)CC1C1=CC=C(O)C=C1 RNAPFFYGJWALAQ-UHFFFAOYSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000009396 suanzaoren Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Marine Sciences & Fisheries (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Animal Husbandry (AREA)
- Pregnancy & Childbirth (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for preventing and treating myopia and/or asthenopia, which is characterized by being prepared from the following raw materials in parts by weight: 8-12 parts of safflower, 8-12 parts of salvia miltiorrhiza, 6-10 parts of ligusticum wallichii, 12-18 parts of white chrysanthemum, 8-12 parts of honeysuckle, 8-12 parts of coptis chinensis, 8-15 parts of green tangerine orange peel, 10-15 parts of mulberry leaves, 15-25 parts of phellinus igniarius, 15-25 parts of lucid ganoderma, 8-12 parts of wolfberry fruit, 15-25 parts of semen cuscutae, 5-12 parts of ginseng, 15-30 parts of astragalus membranaceus, 5-15 parts of semen plantaginis, 5-15 parts of semen cassiae, 5-15 parts of concha haliotidis, 5-15 parts of spina date seeds, 8-16 parts of caltrops, 6-12 parts of oysters, 8-16 parts of periostracum cicada, 5-10 parts of spirulina, 5-15 parts of sea buckthorn, 6-12 parts of ginger, 12-25 parts of placenta hominis, 4-10 parts of mint, 6-12 parts of. The medicinal composition is added with auxiliary materials acceptable for medicinal preparations, and is respectively prepared into an oral medicament and an external medicament, so that the effect of preventing and treating myopia or eye asthenopia can be achieved through oral administration or external application. The product of the invention is simple and easy to be taken orally or externally used, and can benefit more myopes, especially asthenopia patients.
Description
Technical Field
The invention belongs to the field of medicinal preparations, relates to a medicinal composition for protecting eyesight and preventing and treating eye asthenopia, and particularly relates to a medicinal composition for preventing and treating myopia and/or eye fatigue and a preparation thereof.
Background
Myopia is a common eye disease with frequently occurring diseases. Myopia diseases have various causes, such as myopia caused by poor eye use, genetic factors, application of drugs, and the like. In recent years, the incidence rate of the traditional Chinese medicine tends to rise year by year, and the incidence rate of the traditional Chinese medicine is particularly obvious. According to relevant research and report data, the incidence rate of myopia of primary school students in China is 22.8%, that of middle school students is 55.2%, that of high school students is 70.3%, that of myopia of China is 7 hundred million in 2020 is estimated by some people, and the incidence rate is nearly 51%. The myopia is caused by a plurality of reasons, such as large learning pressure, long time for bending over a desk, incorrect posture and distance during reading or writing, too strong or too weak light for reading, improper distance or too long time for watching television, unreasonable diet, genetic factors, environmental factors and the like due to long-time use of computers and mobile phones. The theory of traditional Chinese medicine considers that myopia is caused by visual deterioration due to dysfunction of viscera and meridians, loss of nourishment of eyes, stagnation of qi and blood, and blockage of the chest, such as deficiency of liver and kidney, deficiency of both qi and blood. Since the pathogenesis of myopia is still not well understood, satisfactory results in terms of prevention and treatment are still not achieved. In recent years, the incidence of myopia tends to rise year by year, and especially the incidence of myopia in young and young years is more obvious, so that medical technical workers are required to solve the problem of preventing and treating myopia of the majority of teenagers as early as possible. At present, the methods for treating myopia in the market and medical units are many, most of the methods adopt wearing glasses and health care instruments for treatment, and methods such as vision correction instruments, small-hole glasses, laser therapy, magnetic therapy, electrotherapy, acupuncture and moxibustion and the like are common. At present, some medicines, such as western medicine preparations like atropine eye drops and the like and traditional Chinese medicine preparations like polished sections and the like exist in the market, but the treatment time is long and the effect is not ideal. In severe cases, surgical treatment is mostly adopted, but the surgical treatment has great risk and more sequelae. In the formula preparations of the traditional Chinese medicine, some are mainly used for nourishing liver and kidney, some are mainly used for promoting blood circulation to remove blood stasis, some are mainly used for nourishing yin and promoting the production of body fluid, some are mainly used for dispelling wind and eliminating dampness, clearing heat and purging fire, clearing heat and relieving restlessness, and some are mainly used for tonifying middle-jiao and Qi, and the like. According to the technical scheme disclosed by the prior art, the nutritional deficiency of the eyes is mostly ignored, if the nutrition of the eyes is supplemented, the effects of dredging qi and blood, nourishing liver and kidney, balancing yin and yang, nourishing blood, soothing nerves, resisting oxidation, eliminating free radicals and providing sufficient blood oxygen are combined, so that the eyes are nourished, the asthenopia and the eye muscle spasm disappear, the vision is naturally recovered to be normal, and pseudomyopia at the beginning and middle stages, mixed myopia and astigmatism are mostly formed due to the asthenopia and the ciliary muscle spasm. With the improvement of science and technology, the pace of life and work is accelerated, the popularization of electronic products such as mobile phones, televisions and computers, the long-term use of mobile phones and computers, the long-term watching of televisions, the overnight surfing of internet for chatting and playing, the learning pressure is high, the long-term learning and writing and the like generate eye fatigue due to the excessive use of eyesight. The eye fatigue is a common disease of ophthalmology, the clinical manifestations of the eye fatigue are easy, the symptoms such as eye swelling, eye sleepiness, dryness and puckery, lacrimation, eyebrow arch ache and dizziness appear, make the short distance work or read can't last. The basic symptoms and mechanisms of asthenopia are related to the dysfunction of liver, spleen and kidney caused by various reasons. Liver yin deficiency, liver fire hyperactivity, deficiency of body fluids, and loss of luster of eyes; spleen qi deficiency, failure of ascending clear yang, failure of descending turbid yin, failure of the eyes to warm up the body of clear yang; kidney essence is insufficient and cannot pass through the brain, and brain and marrow have anxiety and essence cannot nourish eyes; physical strength is weak, people can stay in the spirit for a long time, nutrition is not constant, people can not rest due to long-term fatigue, blurred vision and even vision decline are caused, myopia is easy to cause after long-term accumulation, and life and work of people are directly influenced. Eyestrain becomes a public health and social concern for the whole society. Therefore, the traditional Chinese medicine composition in the formula is the basic guarantee for preventing and treating myopia and/or eye fatigue.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for preventing and treating myopia and/or asthenopia, which is prepared from safflower, red sage root, ligusticum wallichii, white chrysanthemum, honeysuckle flower, coptis root, green tangerine orange peel, mulberry leaf, phellinus igniarius, lucid ganoderma, wolfberry fruit, dodder seed, ginseng, astragalus root, plantain seed, cassia seed, abalone shell, spina date seed, caltrop, oyster, cicada slough, spirulina, sea buckthorn, ginger, human placenta, mint, liquorice and pearl powder through processing to prepare an oral preparation.
The invention also aims to provide a pharmaceutical composition for preventing and treating myopia and/or asthenopia, which is prepared from safflower, salvia miltiorrhiza, ligusticum wallichii, white chrysanthemum, honeysuckle, coptis chinensis, green tangerine orange peel, mulberry leaf, phellinus igniarius, lucid ganoderma, medlar, semen cuscutae, ginseng, astragalus mongholicus, semen plantaginis, semen cassiae, concha haliotidis, spina date seed, caltrop, oyster, periostracum cicada, spirulina, sea buckthorn, ginger, human placenta, liquorice, pearl powder, alum, borneol and menthol through processing.
The invention aims to promote the circulation of qi and blood, nourish liver and kidney, tonify nutrition, nourish blood and calm the nerves, provide the best medical effects of sufficient blood oxygen, antioxidation and the like, promote blood circulation, relieve eye muscle spasm, promote vasodilatation, accelerate blood flow, improve blood circulation, dredge channels and collaterals, enhance the regulation and control function, improve the eye muscle function and further obtain the good effect of preventing and treating myopia and/or eye fatigue by taking or externally using the pharmaceutical composition preparation.
In order to realize the invention, the following technical scheme is adopted:
a pharmaceutical composition for preventing and treating myopia and/or asthenopia is characterized by being prepared from the following raw materials in parts by weight: 8-12 parts of safflower, 8-12 parts of salvia miltiorrhiza, 6-10 parts of ligusticum wallichii, 12-18 parts of white chrysanthemum, 8-12 parts of honeysuckle, 8-12 parts of coptis chinensis, 8-15 parts of green tangerine orange peel, 10-15 parts of mulberry leaves, 15-25 parts of phellinus igniarius, 15-25 parts of lucid ganoderma, 8-12 parts of wolfberry fruit, 15-25 parts of semen cuscutae, 5-12 parts of ginseng, 15-30 parts of astragalus membranaceus, 5-15 parts of semen plantaginis, 5-15 parts of semen cassiae, 5-15 parts of concha haliotidis, 5-15 parts of spina date seeds, 8-16 parts of caltrops, 6-12 parts of oysters, 8-16 parts of periostracum cicada, 5-10 parts of spirulina, 5-15 parts of sea buckthorn, 6-12 parts of ginger, 12-25 parts of placenta hominis, 4-10 parts of mint, 6-12 parts of.
The invention discloses a preferable pharmaceutical composition for preventing and treating myopia and/or asthenopia, which is characterized by being prepared from the following raw materials in parts by weight: 10 parts of safflower, 10 parts of salvia miltiorrhiza, 8 parts of ligusticum wallichii, 15 parts of white chrysanthemum, 10 parts of honeysuckle, 10 parts of coptis chinensis, 12 parts of green tangerine peel, 12 parts of mulberry leaves, 20 parts of phellinus igniarius, 20 parts of lucid ganoderma, 10 parts of wolfberry, 20 parts of semen cuscutae, 8 parts of ginseng, 20 parts of astragalus membranaceus, 10 parts of semen plantaginis, 12 parts of semen cassiae, 10 parts of concha haliotidis, 10 parts of spina date seeds, 12 parts of caltrops, 9 parts of oysters, 12 parts of cicada slough, 8 parts of spirulina, 10 parts of sea-buckthorn, 8 parts of ginger, 20 parts of human placenta, 6 parts of mint, 9 parts of liquorice;
the preparation of the pharmaceutical composition comprises the following steps:
(1) respectively cleaning Saviae Miltiorrhizae radix, rhizoma Ligustici Chuanxiong, Coptidis rhizoma, pericarpium Citri Reticulatae viride, folium Mori, Phellinus Linteus, Ganoderma, fructus Lycii, semen Cuscutae, radix astragali, semen plantaginis, semen Cassiae, Concha Haliotidis, semen Ziziphi Spinosae, fructus Tribuli, Concha Ostreae, periostracum Cicadae, Spirulina, fructus Hippophae, rhizoma Zingiberis recens, and Glycyrrhrizae radix, microwave drying, and pulverizing into 40-50 mesh powder;
(2) mixing the medicinal powder obtained in step (1), moistening with edible ethanol for 40-50 hr, and adding edible ethanol at a dose of 0.3-1.5ml/kg-1Collecting percolate at flow rate of (medicinal materials weight), stopping percolating until the percolate turns light yellow, recovering ethanol from percolate, filtering, heating and concentrating to relative density of 1.75-2.25 (50 deg.C), to obtain concentrated solution I; adding purified water 8-10 times of the weight of the medicinal materials into the percolate, decocting with strong fire for 2 hr, decocting with slow fire for 1 hr, filtering to obtain decoction, concentrating the decoction to relative density of 1.72-2.25 (50 deg.C), and collecting concentrated solution II;
(3) cleaning Carthami flos, flos Chrysanthemi, flos Lonicerae, Ginseng radix, and herba Menthae, respectively, microwave drying, grinding into 40-50 mesh powder, mixing the powders, adding edible ethanol, soaking at room temperature for 5-7 days, wherein the amount of ethanol is 5-10 times of the weight of the medicinal materials, and the soaking time is 5-7 days, mixing the three soaking solutions, recovering ethanol, filtering, and concentrating to relative density of 1.15-1.25(50 deg.C) to obtain concentrated solution III; adding purified water 5 times the weight of the medicinal materials into the soaked medicine residues, heating and decocting for 2 hours, taking the decoction, filtering, and concentrating until the relative density is 1.15-1.25(50 ℃), so as to obtain a concentrated solution IV for later use;
(4) microwave drying placenta hominis, grinding into 50 mesh powder, adding 10 times, 8 times and 5 times of normal saline, boiling and extracting for three times, wherein the boiling time is 1 hour each time, mixing the decoctions, filtering, adjusting pH of the filtrate to 3.1-3.2 with 0.1mol hydrochloric acid, standing in a refrigerator for 24-36 hours, precipitating completely, collecting supernatant, filtering, heating and concentrating the filtrate to relative density of 1.05-1.12 (50 deg.C), and collecting concentrated solution V;
(5) mixing the concentrated solutions I, II, III, IV and V obtained in the steps (2), (3) and (4), adding soluble pearl powder in parts by weight, fully and uniformly mixing to obtain a mixed concentrated solution, drying the mixed concentrated solution at low temperature until the water content is less than 5%, cooling, and crushing to obtain the pharmaceutical composition.
The pharmaceutical composition of the present invention can be prepared into oral dosage forms by adding pharmaceutically acceptable carriers during preparation of medicaments, wherein the carriers can be, but are not limited to, starch, sucrose, glucose, fructose, lactose, mannitol, syrup, honey, cellulose and derivatives thereof, propylene glycol, glycerol, polyethylene glycol, dextrin, cyclodextrin and derivatives thereof, gelatin, agar, xanthan gum, acacia gum, tragacanth gum, bletilla striata gum, surfactants, pyrrolidone, calcium carbonate, calcium bicarbonate, sodium bicarbonate, citric acid, talc, magnesium stearate, calcium stearate, etc. Such oral dosage forms include, but are not limited to: oral liquid, syrup, tablet, capsule, granule, pill, and unguent; the tablets comprise plain tablets, sugar-coated tablets, effervescent tablets and buccal tablets; the capsules comprise hard capsules and soft capsules, and the pills comprise water pills and honeyed pills.
The preparation of the invention, preferably oral dosage forms are oral liquid, tablets, capsules, granules and pills, most preferably tablets, such as effervescent tablets, and capsules, such as hard capsules.
The amount of the acceptable carrier added into the pharmaceutical composition can be properly selected according to different preparation formulations, the actual content of the pharmaceutical composition is used for marking the use amount in clinical use, for example, 1g of fine powder of the pharmaceutical composition is directly filled into a capsule or added with beta-cyclodextrin to be uniformly mixed according to a proportion and then filled into a No. 00 capsule, when the use amount is ordered, a patient can take the pharmaceutical composition according to every few capsules, but when the content is marked, the content of the extract of the traditional Chinese medicine contained in each capsule is marked to be 1g so that the patient can clearly and correctly use the extract.
The pharmaceutical composition for preventing and treating myopia and/or asthenopia of the invention has the usage and dosage as follows:
when the traditional Chinese medicine is used for treating the slight myopia, the traditional Chinese medicine is taken 2 times a day, 1g is taken each time, and the traditional Chinese medicine is taken 1 time after breakfast and supper, and 30 days is a treatment course.
When the traditional Chinese medicine is used for treating mild and moderate myopia, the traditional Chinese medicine is taken 3 times a day, 2 g each time, and 30 days as a treatment course after breakfast, lunch and supper each day.
When the eye fatigue is treated, the eye fatigue is taken 2 times a day, 2 g each time, 1 time after breakfast and supper, and 7 days are a treatment course.
The invention also aims to provide a preparation method of the pharmaceutical composition preparation for preventing and treating myopia and/or asthenopia, which is characterized by being prepared from the following raw materials in parts by weight: 8-12 parts of safflower, 8-12 parts of salvia miltiorrhiza, 6-10 parts of ligusticum wallichii, 12-18 parts of white chrysanthemum, 8-12 parts of honeysuckle, 8-12 parts of coptis chinensis, 8-15 parts of green tangerine orange peel, 10-15 parts of mulberry leaves, 15-25 parts of phellinus igniarius, 15-25 parts of lucid ganoderma, 8-12 parts of wolfberry fruit, 15-25 parts of semen cuscutae, 5-12 parts of ginseng, 15-30 parts of astragalus membranaceus, 5-15 parts of semen plantaginis, 5-15 parts of semen cassiae, 5-15 parts of concha haliotidis, 5-15 parts of spina date seeds, 8-16 parts of caltrops, 6-12 parts of oysters, 8-16 parts of periostracum cicada, 5-10 parts of spirulina, 5-15 parts of sea buckthorn, 6-12 parts of ginger, 12-25 parts of placenta hominis, 6-12 parts of liquorice, 4-8 parts of, 4-8 parts of menthol;
the invention discloses a preferable pharmaceutical composition preparation for preventing myopia and/or asthenopia, which is characterized by being prepared from the following raw materials in parts by weight: 10 parts of safflower, 10 parts of salvia miltiorrhiza, 6 parts of ligusticum wallichii, 15 parts of white chrysanthemum, 10 parts of honeysuckle, 10 parts of coptis chinensis, 12 parts of green tangerine peel, 12 parts of mulberry leaves, 20 parts of phellinus igniarius, 20 parts of lucid ganoderma, 10 parts of wolfberry, 20 parts of semen cuscutae, 8 parts of ginseng, 20 parts of astragalus membranaceus, 10 parts of semen plantaginis, 10 parts of semen cassiae, 10 parts of concha haliotidis, 10 parts of spina date seeds, 12 parts of caltrops, 9 parts of oysters, 12 parts of cicada slough, 8 parts of spirulina, 10 parts of sea-buckthorn, 8 parts of ginger, 20 parts of human placenta, 9 parts of liquorice, 6 parts of pearl powder, 6 parts of;
the preparation of the pharmaceutical composition comprises the following steps:
(1) respectively cleaning Carthami flos, Saviae Miltiorrhizae radix, rhizoma Ligustici Chuanxiong, flos Chrysanthemi, flos Lonicerae, Coptidis rhizoma, pericarpium Citri Reticulatae viride, folium Mori, Phellinus Linteus, Ganoderma, fructus Lycii, semen Cuscutae, Ginseng radix, radix astragali, semen plantaginis, semen Cassiae, Concha Haliotidis, semen Ziziphi Spinosae, fructus Tribuli, Concha Ostreae, periostracum Cicadae, Spirulina, fructus Hippophae, rhizoma Zingiberis recens, and Glycyrrhrizae radix, microwave drying, and pulverizing into 80 mesh powder; mixing the medicinal powder, and adding the medicinal powder into the mixture according to the weight ratio of 1: 10. 1: 7. 1: soaking 5V/V ethanol (30-65%) at 40-42 deg.C for three times (first 72 hr, second 48 hr, and third 24 hr) in ethanol, mixing the soaking solutions for 3 times, filtering, and recovering ethanol to obtain extractive solution;
(2) and (3) soaking the filter residue obtained in the step (1) for three times according to the weight of the medicinal materials of 1: adding purified water at a ratio of 15-20, decocting with strong fire for 3 hr, decocting with slow fire for 1 hr, filtering to obtain decoction, and concentrating to obtain concentrated solution with specific gravity of 1.15 (50 deg.C);
(3) microwave drying placenta hominis, pulverizing into 50 mesh powder, adding 10 times, 8 times and 5 times of normal saline, boiling and extracting for three times (each time for 1 hr), mixing the three decoctions, filtering, adjusting pH to 3.1-3.2 with 0.1mol hydrochloric acid, placing in refrigerator, standing at 1-2 deg.C for 24-36 hr, collecting supernatant after the solution is completely precipitated, and filtering to obtain filtrate;
(4) mixing the extract obtained in the step (1) and the concentrated solution obtained in the step (2) with the filtrate obtained in the step (3), concentrating by thin film evaporation to obtain a thick paste with the water content of 25 percent by weight, drying the thick paste in vacuum at 48-50 ℃, crushing and sieving to obtain 100-mesh powder;
(5) grinding borneol and menthol in parts by weight together, sieving the ground mixture with a 300-mesh sieve, mixing the ground mixture with water-soluble pearl powder in parts by weight, uniformly grinding the mixture, and adding the mixture into the 100-mesh powder obtained in the step (4) to be fully and uniformly blended to obtain the pharmaceutical composition.
When the pharmaceutical composition is prepared into a preparation, a pharmaceutically acceptable carrier can be added to prepare an external preparation;
the carrier can be, but is not limited to, water, ethanol, propylene glycol, polyethylene glycol, tween 80, methyl cellulose, sodium carboxymethyl cellulose, talcum powder, kaolin, vegetable oil, surfactant, glycerol, liquid paraffin, lanolin, vaseline, etc.;
the pharmaceutical composition of the present invention may be any pharmaceutical external preparation including, but not limited to, solutions, powders, suspensions, ointments, plasters, creams, sprays, patches.
The external preparation of the present invention is preferably an ointment, a spray or a patch.
Most preferred is a patch.
The external preparation can be added with pharmaceutically acceptable carriers as required to prepare formulations such as ointment, spray, paste and the like, the most preferable paste is taken as the best choice in the embodiment of the invention, the using method is simple, the operation is easy, and the external preparation has obvious effects of improving and relieving eye fatigue. The eye pasting is a new method for treating eye diseases by percutaneous absorption, the medicine is absorbed into capillary vessels through local skin and directly enters the receptor part of the target area to play a local role, however, the skin around the eye is the weakest and most sensitive part of the human skin, the medicine is easy to permeate and diffuse into the capillary vessels, small blood vessels and lymphatic vessels in the eye, and is quickly absorbed and distributed to each tissue in the eye, and the medicine is continuously released into the eye more and absorbed more because of the long retention time around the eye, the medicine concentration in the eye is higher, and the treatment effect is better.
The raw materials used in the invention have the pharmacology as follows:
the Carthami flos is dried flower of Carthamus tinctorius L of Compositae. Nature, flavor and meridian tropism: pungent and warm. It enters heart and liver meridians. Carthami flos has effects of promoting blood circulation, dredging channels, removing blood stasis and relieving pain. It is commonly used for amenorrhea, dysmenorrhea, lochiorrhea, mass, chest stuffiness, cardialgia, abdominal pain due to stasis, stabbing pain in chest and hypochondrium, traumatic injury, sore and ulcer with swelling and pain. Safflower enters heart and liver meridian and blood system, has the property of pungent, cool and unblocking, functions of promoting blood circulation and unblocking meridians, dissipating blood stasis and alleviating pain, is the essential herb for promoting blood circulation and removing blood stasis, and is also good at promoting blood circulation and removing blood stasis, and eliminating mass and dissipating stagnation, and is also commonly used for mass and abdominal mass caused by stasis (pharmacopoeia of the people's republic of China, clinical medication need, Chinese medicinal tablet roll, 2015 version 843P).
The Saviae Miltiorrhizae radix is dried root and rhizome of Salvia milirhizorrhiza bge. Bitter and slightly cold in nature. It enters heart and liver meridians. The salvia miltiorrhiza has the functions of activating blood and dissolving stasis, stimulating the menstrual flow and relieving pain, clearing away the heart fire and relieving restlessness, cooling blood and eliminating carbuncle. Can be used for treating thoracic obstruction, cardialgia, abdominal pain, hypochondriac pain, abdominal mass, pain due to pyretic arthralgia, vexation, insomnia, menoxenia, dysmenorrhea, amenorrhea, and pyocutaneous disease with swelling and pain. Salvia miltiorrhiza, which is bitter in taste and cool in nature, enters heart and liver meridians and enters blood system mainly, has the functions of activating blood and removing stasis, has a wide application range and is suitable for various syndromes caused by blood stasis obstruction. Salvia miltiorrhiza has the functions of cooling blood heat, clearing heart fire and calming the mind. Is suitable for hyperpyrexia and coma caused by heat entering nutrient-blood, and uneasiness and palpitation and insomnia caused by blood failing to nourish heart (pharmacopoeia of people's republic of China, clinical medication palpation, Chinese medicinal tablet roll, 2015 version 836P).
The rhizoma Ligustici Chuanxiong is dried rhizome of Ligusticum chuanxiong Hort of Umbelliferae. Chuan Xiong is pungent in flavor and warm in nature. It enters liver, gallbladder and pericardium meridians. Has the functions of promoting blood circulation, promoting qi circulation, dispelling pathogenic wind and relieving pain. Can be used for treating thoracic obstruction, cardialgia, stabbing pain in chest and hypochondrium, traumatic injury, menoxenia, amenorrhea, dysmenorrhea, abdominal mass, headache, and rheumatalgia. Chuan Xiong is pungent and warm in property and has the actions of activating blood and moving qi, so it is called as "blood-qi-flowing-in-blood-qi-flowing medicine" (the book Cao Hui Yan). It can promote blood circulation, remove blood stasis, dredge collaterals, and treat heart meridian obstruction, thoracic obstruction, and cardiodynia; it is also indicated for chest and hypochondrium stabbing pain due to liver qi stagnation, because it can move qi, relieve qi stagnation and alleviate pain. It is also indicated for abdominal mass and pain, and has the actions of activating blood and resolving stasis, and eliminating mass and dissipating nodulation. Chuan Xiong can also activate blood and dissipate blood stasis, resolve swelling and alleviate pain, and is commonly used for traumatic injuries and pain caused by stasis. Chuan Xiong Xin san has the functions of dispelling wind, promoting blood circulation and removing blood stasis, and bypassing collaterals (pharmacopoeia of the people's republic of China, clinical medication palpation, volume of Chinese medicinal decoction, 2015 version 811P).
The white chrysanthemum is also called chrysanthemum, chamomile, chrysanthemum morifolium, Huai chrysanthemum, tea chrysanthemum and chrysanthemum. The chrysanthemum is divided into yellow chrysanthemum and white chrysanthemum. Generally, Huang Ju Hua is used for dispelling wind-heat, Bai Ju Hua is suitable for pacifying liver, clearing liver and improving vision, so the Ju Hua adopted in the invention is Bai Ju Hua. The flos Chrysanthemi is dried head-like inflorescence of Chrysanthemum morifolium Ramat. Chrysanthemum is sweet, bitter and slightly cold in nature and taste. It enters lung and liver meridians. Has the functions of dispelling wind, clearing heat, calming liver, improving eyesight, clearing heat and detoxicating. Can be used for treating wind-heat type common cold, headache, giddiness, conjunctival congestion, swelling and pain, dim eyesight, sore, carbuncle, and toxic swelling. The chrysanthemum can disperse wind-heat in lung meridian but has weak power of dispersing exterior pathogen. Chrysanthemum is slightly cold in nature and enters liver meridian to clear liver heat and calm liver yang, so it is commonly indicated for liver yang hyperactivity, headache and vertigo. Chrysanthemum is light in weight, slightly bitter in taste and capable of releasing heat, slightly cold in nature and clearing heat, enters liver meridian, and can disperse liver meridian wind-heat and clear liver heat to improve vision, so it can be used for treating conjunctival congestion and swelling pain caused by liver meridian wind-heat or liver fire attacking upwards. For deficiency of essence and blood of liver and kidney, blurred vision, it is often combined with liver and kidney-nourishing, yin-tonifying and vision-improving herbs (pharmacopoeia of the people's republic of China, clinical medicine need to know, volume of Chinese medicine tablets, 2015 edition 129-130P).
The flos Lonicerae is dried bud or flower with initial bloom of Lonicera japonica Thunb. Honeysuckle flower is sweet in nature and taste and cold in nature. It enters lung, heart and stomach meridians. Has the functions of clearing away heat and toxic material and dispelling wind and heat. Can be used for treating carbuncle, furuncle, sore throat, erysipelas, toxic heat, dysentery, wind-heat type common cold, epidemic febrile disease, and fever. Honeysuckle flower is sweet in taste and cold in nature, fragrant in smell, and mild in drug property, enters lung, heart and stomach meridians, clears heat without damaging qi, and dissolves toxin without damaging yin, is good at clearing qi and dividing heat evil, penetrating nutrient and activating qi, relieving fire toxin, eliminating carbuncle and swelling, and has strong effects of clearing heat and removing toxicity, and is an essential drug for treating pyocutaneous disease. It is commonly indicated for abscess, deep-rooted boil, sore throat, erysipelas and other heat-toxin syndromes. It is also a good herb for wind-heat type common cold, epidemic febrile disease and fever because it can disperse the wind, disperse the pathogenic heat in lung channel and expel the pathogenic heat from the exterior. For heat entering nutrient-blood, crimson tongue with coma, restlessness and insomnia, it also has the effect of transforming nutrient-qi (pharmacopoeia of the people's republic of China-clinical application of medicine, volume of decoction of Chinese herbs, version 235P 2015).
The Coptidis rhizoma is dried rhizome of Coptis chinensis Franch, Coptis deltoidea C.Y.Cheng et Hsiao or Coptis Teeta wall of Ranunculaceae. Huang Lian is bitter in flavor and cold in nature. It enters heart, spleen, stomach, liver, gallbladder and large intestine meridians. Has the functions of clearing heat, drying dampness, purging fire and detoxifying. Can be used for treating damp-heat distention and fullness, emesis, acid regurgitation, dysentery, jaundice, hyperpyrexia, excessive heart-fire, vexation, insomnia, palpitation, hematemesis, epistaxis, conjunctival congestion, toothache, diabetes, carbuncle, swelling, and furuncle. Coptis root, rhizoma Coptidis, being bitter and cold, enters liver meridian and clears liver fire, can be used for vomiting and acid regurgitation due to liver depression transforming into fire and transverse adverse flow affecting stomach. Coptis root, rhizoma Coptidis, having the actions of clearing heat and drying dampness, purging fire and removing toxicity, excels in treating furunculosis, and is commonly indicated for exuberant heat-toxicity, red and swollen eyes, sores in the mouth and tongue, carbuncle and furuncle (pharmacopoeia of the people's republic of China, clinical medication palpation, volume of Chinese medicinal decoction, 2015 version 195P).
The pericarpium Citri Reticulatae viride is pericarp of dried young fruit or immature fruit of Citrus reticulata Blanco of Rutaceae and its cultivar. Qing Pi is bitter and pungent in flavor and warm in nature. It enters liver, gallbladder and stomach meridians. Has the functions of soothing liver, breaking qi, removing food retention and resolving stagnation. Can be used for treating distending pain in chest and hypochondrium, hernia pain, nodules of breast, mammary abscess, food stagnation, qi stagnation, and abdominal pain. Qing Pi is pungent and warm in property, bitter in flavor and purgative in descending, and drastic in property, and is a herb of qi system of liver and gallbladder, and has the actions of dispersing stagnated liver qi and gallbladder, breaking qi stagnation, dissipating nodulation and relieving pain, so it is especially suitable for treating distending pain in chest and hypochondrium, hernia pain, and swelling and pain in breast caused by liver depression and qi stagnation (pharmacopoeia of the people's republic of China, clinical palpation of medicine, Chinese medicinal decoction roll, 2015 edition P672).
The folium Mori is dry leaf of Morus alba L. Mulberry leaves are sweet, bitter and cold in nature and taste. It enters lung and liver meridians. Has the functions of dispelling wind and heat, clearing away lung heat, moistening dryness, clearing liver and improving vision. Can be used for treating wind-heat type common cold, lung heat type cough, dizziness, headache, conjunctival congestion, and dim eyesight. Mulberry leaf, folium Mori is bitter and cold, enters liver meridian, and has the action of pacifying and descending liver yang, so it can be used for treating hyperactivity of liver yang, headache, vertigo, heaviness of head, light feet, restlessness and irritability. Mulberry leaf, folium Mori, being bitter and cold in property, can clear heat from the liver channel, clear liver heat, and nourish yin to improve vision, so it is commonly indicated for conjunctival congestion, pain and lacrimation due to wind-heat attacking the upper part of the body and up-flaming of liver fire. For deficiency of liver and kidney essence and blood, blurred vision, it is often combined with essence and blood tonics (pharmacopoeia of the people's republic of China, clinical palpation, volume of Chinese medicinal tablets, 2015 version 127P).
Phellinus linteus, also called Phellinus linteus and Phellinus linteus, is the fruiting body of Phellinus linteus Phellinus igniarius (L.ex Fr.) Quel. Phellinus Linteus is sweet, pungent, bitter and cold in nature. It enters liver and kidney meridians. Has effects in promoting blood circulation, stopping bleeding, resolving phlegm, and relieving diarrhea. It is suitable for metrorrhagia, stranguria with blood, diarrhea, rectocele, leukorrhagia, amenorrhea, abdominal mass, diarrhea due to spleen deficiency. The literature states that: phellinus linteus is rich in flavonoids such as naringenin, sakuranetin, and eriodictyol; coumarin components such as coumarins and hyoscyamine; also contains agaricic acid, veratrine, mushroom acid, ergosterol, amino acid, etc. The pharmacology of the liver-protecting drug has the liver-protecting effect: phellinus igniarius is capable of obviously relieving degeneration and necrosis of liver cells, maintaining normal structure of liver tissues and promoting recovery of liver functions; scavenging free radicals: phellinus igniarius intracellular polysaccharide can increase the defense function of organism against free radical injury (Wang Guo Qiang compiled "national Chinese herbal medicine Association" volume three, national health Press, 3 rd edition 2 month 2014, 515P).
Ganoderma is dried fruiting body of Ganoderma Lucidum Canoderma Lucidum (Leys. ex Fr.) Karst. or Ganoderma sinense Zhao, Xu et Zhang. Ganoderma lucidum is sweet in nature and mild in flavor. It enters heart, lung, liver and kidney meridians. Has the functions of invigorating qi, tranquilizing, relieving cough and asthma. Can be used for treating restlessness, insomnia, palpitation, cough due to lung deficiency, asthenia, short breath, and anorexia. Ganoderma lucidum is sweet in flavor and can tonify heart qi and calm heart spirit, so it can be used for treating unsteadiness of heart-mind, insomnia, palpitation due to malnutrition of heart-spirit. Ganoderma enters lung and kidney meridians to tonify qi of lung and kidney, and can relieve cough and dyspnea, so it is often indicated for cough and dyspnea due to lung deficiency, shortness of breath due to asthenia, poor appetite, etc. Ganoderma has tranquilizing, antiepileptic, brain tissue protecting, immunity enhancing, antitumor, liver protecting, blood sugar lowering, diabetes complication inhibiting, antiaging, blood lipid reducing, atherosclerosis resisting, and kidney protecting effects (pharmacopoeia of people's republic of China, clinical application requires knowledge, Chinese medicinal tablet roll, 2015 edition 1004-1005P). The literature also discloses: from the 70 s of the 20 th century, more than 20 national medical research units such as Beijing medical college, Chinese medical academy of sciences, Beijing institute of pharmacy, Sichuan institute of antibiotics, Shanghai medical university, etc. have systematically developed the researches on the pharmacology, pharmacological action, and curative effect of Ganoderma lucidum in succession, and many effects of Ganoderma lucidum are clarified and known in depth. The research result shows that: the ganoderma lucidum has various pharmacological activities and curative effects, and has the effects of improving the organism immunity, inhibiting the growth of tumors, improving myocardial contractility, accelerating blood circulation, improving blood microcirculation, improving hemoglobin oxygen carrying and supplying, expanding arteriovenous oxygen difference, calming the liver, detoxifying, improving the organism physiological function, reducing blood pressure, blood fat and blood sugar, calming the nerves, relieving spasm and blood viscosity. The efficacy of Ganoderma lucidum recorded in Shennong Ben Cao Jing (Shen nong's herbal Jing) has been fully proven (Chen Guo Liang, Chen Hui Shu (Ganoderma lucidum treating diseases), third edition, Shanghai science and technology literature Press, 2007, 4 months, page 4).
Fructus Lycii is dried mature fruit of Lycium barbarum L. Wolfberry fruit is sweet in nature and mild in taste. It enters liver and kidney meridians. Has effects in nourishing liver and kidney, replenishing vital essence, and improving eyesight, and can be used for treating asthenia essence deficiency, soreness of waist and knees, vertigo, tinnitus, sexual impotence, spermatorrhea, internal heat, diabetes, blood deficiency, sallow complexion, and blurred vision. Wolfberry fruit, fructus Lycii, sweet in taste and neutral in nature, enters liver and kidney meridians, excels in nourishing kidney essence and tonifying liver blood, and is said in Ben Cao Jing Shu (materia Medica of materia Medica): "is the essential herb for fatigue, internal heat and invigoration due to deficiency of liver and kidney yin, and can be used for treating soreness and weakness of waist and knees, vertigo, tinnitus, spermatorrhea, infertility and blurred vision caused by deficiency of liver and kidney essence and blood (pharmacopoeia of the people's republic of China, clinical medication need, volume of traditional Chinese medicine tablets, 2015 edition 1230P).
Semen Cuscutae is dried mature seed of south semen Cuscutae Cuscuta australis R.Br. or semen Cuscutae Cuscuta chinensis Lam. The dodder seed is pungent, sweet and mild in nature. It enters liver, kidney and spleen meridians. Has the effects of tonifying liver and kidney, securing essence, reducing urination, preventing miscarriage, improving eyesight and stopping diarrhea. Can be used for treating kidney deficiency, soreness of waist and knees, sexual impotence, spermatorrhea, enuresis, frequent micturition, fetal leakage due to kidney deficiency, fetal irritability, blurred vision, tinnitus, and spleen and kidney deficiency. The dodder seed is pungent and sweet and neutral, enters liver, kidney and spleen channels, can moisten and tonify in sweet, has mild property, can tonify kidney yang and kidney yin, is a product for tonifying yin and yang, has the functions of tonifying liver and kidney, securing essence and reducing urination, and is used for treating liver and kidney deficiency and soreness and weakness of waist and knees; dodder seed, semen Cuscutae, also has the actions of tonifying kidney and liver, promoting the injection of essence and blood to improve vision and hearing, so it is indicated for blurred vision and tinnitus due to liver and kidney deficiency (pharmacopoeia of the people's republic of China, clinical medicine palpation, volume of Chinese medicinal tablets, 2015 th edition 1163P).
Ginseng radix is dried root and rhizome of Panax ginseng C.A.Mey. Ginseng is sweet in nature, slightly bitter in taste and slightly warm in nature. It enters spleen, lung, heart and kidney meridians. Has effects of invigorating primordial qi, restoring pulse, relieving depletion, invigorating spleen, benefiting lung, promoting fluid production, nourishing blood, tranquilizing mind, and improving intelligence. Can be used for treating asthenia, collapse, cold limbs, weak pulse, spleen deficiency, anorexia, lung deficiency, cough, asthma, body fluid deficiency, thirst, internal heat, diabetes, deficiency of both qi and blood, asthenia, palpitation, insomnia, sexual impotence, and cold womb. Ginseng, sweet in taste, slightly bitter and warm in nature, mainly enters spleen, lung, heart and kidney meridians. It has a wide range of qi tonics, and can tonify both original qi and lung qi, spleen qi, heart qi and kidney qi, and its action of tonifying original qi, restoring pulse and relieving depletion can not be substituted by any drug, so it is the essential drug for saving critical depletion. Ginseng radix has effects of invigorating primordial qi, nourishing heart-qi, tranquilizing mind, improving intelligence, and tranquilizing mind, and can be used for treating insomnia and amnesia due to heart-qi deficiency or deficiency of heart-kidney qi and deficiency of both heart and spleen. Ginseng, sweet and warm in taste, has the effects of invigorating primordial qi and replenishing qi to produce blood, and has the effect of tonifying both qi and blood, so it can be used for treating spleen and stomach qi deficiency, deficiency of source of transformation, and sallow complexion due to blood deficiency; it can also tonify qi to strengthen yang, so it is indicated for deficiency of primordial qi, decline of vital gate fire, impotence and cold womb. In a word, the action of ren Shen is mainly to tonify primordial qi, lung qi, spleen qi, heart qi, kidney qi, promote fluid production, induce tranquilization and benefit intelligence, so it is the first herb for consumptive disease internal injury (pharmacopoeia of people's republic of China, clinical medication need, volume of Chinese medicinal tablets, 2015 edition 1079P).
The radix astragali is dried root of Astragalus membranaceus (Fisch.) Bge. of Leguminosae family or Astragalus membranaceus (Fisch.) Bge. of Hsiao. Astragalus root, radix astragali is sweet in nature and taste, and is slightly warm. It enters liver and spleen meridians. Has the functions of invigorating qi, invigorating yang, consolidating superficial resistance, arresting sweating, inducing diuresis, relieving swelling, promoting fluid production, nourishing blood, activating stagnancy, relieving arthralgia, expelling toxin, expelling pus, healing sore and promoting granulation. Can be used for treating deficiency of vital energy, asthenia, anorexia, loose stool, collapse of middle-warmer energy, chronic diarrhea, rectocele, hematochezia, spontaneous perspiration due to exterior deficiency, edema due to qi deficiency, internal heat, diabetes, blood deficiency, hemiplegia, arthralgia, numbness, carbuncle, cellulitis, and intractable ulcer. Huang Qi is sweet and warm in taste, enters spleen meridian and is good at tonifying spleen qi and lifting middle-jiao yang, so it is the most suitable for deficiency of middle-jiao qi, weakness of spleen and earth and sinking of clear qi (Ben Cao Zheng Yi). Astragalus root, radix astragali, being sweet and slightly warm, has the functions of tonifying qi and raising yang, promoting yin growth by covering yang, and promoting qi and blood generation, so it has the functions of tonifying qi and generating blood, and is commonly used for treating internal injury due to overstrain, deficiency of qi and blood, blood deficiency and yang floating, muscle heat and red face, blood deficiency and fever due to large and weak pulse, and excessive thinking, overstrain, heart and spleen injury due to overstrain, deficiency of both qi and blood, sallow complexion, palpitation and insomnia. Qi moving and blood moving, qi stagnation and blood coagulation, astragalus root has the action of tonifying qi and qi moving (pharmacopoeia of the people's republic of China, clinical medication palpation, volume of Chinese medicinal tablets, 2015 edition 1093P).
Plantago asiatica L or Plantago depressa Willd dried mature seeds of Plantago asiatica L. Plantain seed, semen plantaginis is sweet in nature and cold in flavor. It enters liver, kidney, lung and small intestine meridians. Has effects in clearing away heat, promoting urination, treating stranguria, eliminating dampness, relieving diarrhea, improving eyesight, and eliminating phlegm. Can be used for treating pyretic stranguria, pain, edema, swelling, summer-heat dampness, diarrhea, conjunctival congestion, swelling and pain, and cough due to phlegm-heat. Che Qian Zi is sweet and bland in flavor and good at excreting dampness and heat, clearing heat and promoting the flow of qi and cold, and directing dampness and heat downward and flowing out of urine. Edema, fullness and distention due to damp-heat accumulation in the interior, difficult urination, etc. It is especially suitable for treating stranguria due to downward flow of damp-heat. Che Qian Zi enters small intestine meridian and can excrete clear and turbid urine and induce diuresis to make stool solid. So it is indicated for summer-heat-damp diarrhea due to difficulty in urination caused by dampness in large intestine. Che Qian Zi enters liver and passes kidney, so it can clear liver heat and improve vision, so it is indicated for blood-shot eyes with swelling and pain. Che Qian Zi enters lung meridian and can clear lung heat, resolve phlegm turbidity and relieve cough, so it is indicated for cough with profuse phlegm due to lung heat (pharmacopoeia of people's republic of China, clinical need for medication, volume of Chinese medicinal tablets, 567P 2015).
The semen Cassiae is dried mature seed of Cassia obtusifolia L. or Cassia tora L. of Leguminosae. Cassia seed, semen Cassiae, is sweet, bitter, salty and slightly cold in nature and taste. It enters liver and large intestine meridians. Has the functions of clearing away heat, improving eyesight, moistening intestine and relaxing bowels. Can be used for treating conjunctival congestion, photophobia, lacrimation, headache, vertigo, dim eyesight, and constipation. Cassia seed, semen Cassiae, bitter in flavor and cold in property, can clear heat and nourish yin, not only can clear liver fire, but also can nourish liver yin, is a good product for improving eyesight, and can be applied to both deficiency and excess eye diseases. Shen nong Ben Cao Jing carries its feature of treating blindness, eye irritability, red and white membrane, red and painful eyes and lacrimation, so it is commonly indicated for conjunctival congestion, painful eyes, photophobia and lacrimation caused by wind-heat attacking upwards; conjunctival congestion and swelling pain due to up-disturbance of liver fire, headache and vertigo, and blurred vision due to yin deficiency of liver and kidney (pharmacopoeia of the people's republic of China, clinical need for medicine, volume of Chinese medicinal tablets, 2015 version 177 and 178P).
The Concha Haliotidis is shell of Haliotis diversicolor Reeve, Haliotis discus hannai Ino, Haliotis ovirina Gmelin, Haliotis asini ruber (Leach), Haliotis asini Linnaeus or Haliotis laevigata (Donovan) of Haliotis pall. Shi Jue Ming is salty in flavor and cold in nature. It enters liver meridian. Has the functions of calming the liver, suppressing yang hyperactivity, clearing liver and improving vision. Can be used for treating headache, vertigo, conjunctival congestion, nebula, blurred vision, and night blindness. Shi Jue Ming enters liver meridian due to salty cold and sinking property, excels in descending liver yang and clearing liver heat and tonifying liver yin, so it is the essential herb for cooling liver and relieving liver in Yi Xue Zhong xi Lu, so it is good at treating headache and vertigo due to liver yang hyperactivity caused by yin deficiency and deficiency of liver and kidney. Shi Jue Ming can clear liver fire, benefit liver yin to improve vision and remove nebula, is a common product for clearing liver and improving vision, and can be used for treating red eyes, swelling and pain, nebula, blurred vision, and other symptoms, no matter deficiency or excess, so it is the essential herb for treating eye diseases; it is also indicated for blood-shot eyes with swelling and pain due to up-flaming of liver fire because of its strong action of clearing liver fire (pharmacopoeia of the people's republic of China, clinical need for medication, volume of Chinese medicinal tablets, 2015 version 1021P).
The semen Ziziphi Spinosae is dry mature seed of Ziziphus jujuba Mill.var. spinosa (Bunge) Hu ex H.F.Chou belonging to Rhamnaceae. Suan Zao ren is sweet, sour and mild in nature. It enters liver, gallbladder and heart meridians. Has the functions of nourishing heart, tonifying liver, calming heart, tranquilizing mind, arresting sweating and promoting the production of body fluid. Can be used for treating vexation, insomnia, palpitation, dreaminess, asthenia, hyperhidrosis, body fluid deficiency, and thirst. The spina date seed is sweet in taste and capable of tonifying, enters liver and heart meridians, has the effects of nourishing heart yin and benefiting liver blood to calm heart and tranquilize mind, is an essential heart-nourishing and tranquilization medicine and is mainly used for treating palpitation, vexation and insomnia, dreaminess and the like caused by insufficient heart-liver yin blood, heart failure and mental retardation (the pharmacopoeia of the people's republic of China, clinical medication need, a traditional Chinese medicine tablet roll, 2015 version 1000-plus 1001P).
The fructus Tribuli is dried mature fruit of Tribuli terrestris L. The caltrop is pungent, bitter and slightly warm in nature; has little toxicity. It enters liver meridian. Has effects in calming liver, relieving depression, promoting blood circulation, expelling pathogenic wind, improving eyesight, and relieving itching. Can be used for treating headache, vertigo, distending pain in chest and hypochondrium, milk retention, mammary abscess, conjunctival congestion, nebula, rubella and pruritus. Tribulus terrestris, bitter in flavor and descending in order to enter liver meridian, has the action of pacifying liver yang, so it can be used to treat hyperactivity of liver yang, headache and vertigo. Tribulus terrestris is pungent in flavor and capable of dispersing and good at dispelling wind-heat in liver channel to improve vision and remove nebula, and is an essential herb for treating wind-heat and improving vision in the book Jing Yuan (pharmacopoeia of the people's republic of China, clinical medicine need know, volume of Chinese medicinal tablets, version 1029 of 2015, 1030P).
The Concha Ostreae is the shell of Ostrea gigas Thunberg, Ostrea talienhanensis Crosse or Ostrea rivularis Gould of Ostrea gigas of Ostrea. Oyster is salty in flavor and slightly cold in nature. It enters liver, gallbladder and kidney meridians. Has the functions of tranquilizing, subduing yang, nourishing yin, softening hardness and dissipating stagnation. It is used for treating palpitation, insomnia, vertigo, tinnitus, scrofula, phlegm nodule, abdominal mass, etc. Oyster is salty and cold in nature, enters liver and kidney, astringes soul, relieves convulsion and tranquilizes, so it is indicated for restlessness, palpitation and insomnia. Oyster has the functions of calming liver and suppressing yang, nourishing yin and clearing heat due to the accumulation of salty cold and sinking of the liver and kidney meridians, and is mainly used for treating dizziness, dysphoria, tinnitus and other symptoms caused by water retention, yin deficiency and yang hyperactivity (pharmacopoeia of the people's republic of China, clinical medication need, traditional Chinese medicine decoction, 2015 version 1024P).
The periostracum Cicadae is peel shell of Cryptotympana pustulata Fabricius of cicadae insect when nymph emergence. Cicada slough is sweet in nature and cold in flavor. It enters lung and liver meridians. Has effects in dispelling pathogenic wind and heat, relieving sore throat, promoting eruption, improving eyesight, removing nebula, and relieving spasm. Can be used for treating wind-heat type common cold, pharyngalgia, hoarseness, measles without adequate eruption, rubella, pruritus, conjunctival congestion, nebula, convulsion, and tetanus. Chan tui enters liver meridian and is good at dispelling wind-heat from liver meridian and improving vision and removing nebula, so it is indicated for blood-shot eyes with swelling pain and nebula covering eyes due to wind-heat attacking or liver fire flaming up. In addition, it has the actions of tranquilizing and allaying excitement (pharmacopoeia of the people's republic of China, clinical medication need, volume of Chinese medicinal tablets, 2015 edition 125P).
The Spirulina is dried body of Spirulina platensis (Nords) Geitlerr of Spirulina of Oscillatoriaceae. Spirulina is salty, sweet and mild in nature and taste. It enters liver, spleen and kidney meridians. Has the functions of benefiting qi, nourishing blood, invigorating spleen and tonifying kidney. Is suitable for adjuvant treatment of asthenia, malnutrition, anemia, leukopenia, platelet decrease, hyperlipidemia, and hypoimmunity caused by tumor chemotherapy and radiotherapy. The spirulina contains protein and polysaccharide, and the protein mainly comprises isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and the like. In addition, the beverage also contains fat, chlorophyll, carotenoid, phycocyanin, vitamin A, B1, B2, B6, B12, E, nicotinic acid, creatine, r-linolenic acid, calcium pantothenate, folic acid, calcium, iron, zinc, magnesium and the like (Wang Qiang's Ming Shui (national Chinese herbal medicine assembly), volume three, people's health Press, 3 rd edition 2 month 2014, 669-. The spirulina contains abundant nutrient components and contains vitamin E which is richer than malt, and a plurality of clinical trials prove that the vitamin E has the functions of resisting oxidation, aging and cancers, and can enhance the immunity and prevent the formation of blood clots. The spirulina contains various physiological active components, such as polysaccharide, phycocyanin, vitamin, beta-carotene, gamma-linolenic acid (GLA) and some enzymes, so that the spirulina has various health care functions of anti-aging, effective elimination of in-vivo free radicals, anti-fatigue, antivirus and the like (Zhang Lianfu, Ji hongwu mainly compiles 'resources and bioactive components for both medicine and food', chemical industry press, 9 th edition 2005, 256-plus 260P).
The fructus Hippophae is dried mature fruit of Hippophae rhamnoides L. Seabuckthorn is sour, astringent and warm in nature. It enters spleen, stomach, lung and heart meridians. Has the functions of invigorating spleen, promoting digestion, relieving cough, eliminating phlegm, promoting blood circulation and removing blood stasis. Can be used for treating spleen deficiency, anorexia, abdominal pain due to dyspepsia, cough with excessive phlegm, thoracic obstruction, cardialgia, blood stasis, amenorrhea, and traumatic injury with blood stasis and swelling. Seabuckthorn fruit enters heart meridian, has the functions of activating blood circulation and removing blood stasis, and can be used for treating various blood stasis syndromes such as thoracic obstruction, cardiodynia, traumatic injury, irregular menstruation and the like. It is more effective in activating blood and dredging collaterals, so it is used for chest impediment, stasis and pain (pharmacopoeia of the people's republic of China, clinical medication need, volume of decoction of Chinese herbs, 1121P 2015 version).
The rhizoma Zingiberis recens is fresh rhizome of Zingiber officinale Rosc. Ginger is pungent in nature and slightly warm in taste. It enters lung, spleen and stomach meridians. Has effects in relieving exterior syndrome, dispelling cold, warming middle warmer, relieving vomit, eliminating phlegm, relieving cough, and removing toxic materials of fish, and can be used for treating wind-cold type common cold, stomach cold type emesis, cough due to cold phlegm, and fish chelate poisoning. The pharmacology is as follows: has antipyretic, analgesic, antiinflammatory, immunosuppressive, antiemetic, gastric mucosa protecting, tranquilizing, anticonvulsive, cardiovascular system affecting, antibacterial, and antioxidant effects (pharmacopoeia of the people's republic of China, clinical application, decoction of Chinese medicinal materials, 2015 edition 85-87P).
Placenta hominis is the dried placenta of healthy people. Placenta hominis is sweet, salty and warm in nature. It enters lung, liver and kidney meridians. Has the functions of warming kidney, replenishing essence, benefiting qi and nourishing blood. Can be used for treating asthenia, marasmus, sexual impotence, spermatorrhea, infertility, olignosis, chronic cough, asthma, hectic fever, cough, sallow complexion, anorexia, and short breath. Human placenta is a product with blood and meat emotion, is surplus from pregnancy caused by essence and blood, is sweet and salty in nature and warm, enters the three channels of lung and liver and kidney, controls qi in the lung, stores blood in the liver and stores essence in the kidney, and is a product for warming the kidney, replenishing essence, tonifying qi and nourishing blood; placenta hominis has the effects of tonifying lung qi and replenishing essence and blood, and is commonly indicated for deficiency of both lung and kidney (pharmacopoeia of the people's republic of China, clinical medication palpation, volume of decoction of Chinese medicinal herbs, 2015 edition 1179P).
The herba Menthae is dried aerial part of Mentha haplocalyx Briq. The mint is pungent in flavor and cool. It enters lung and liver meridians. Has effects in dispelling pathogenic wind and heat, refreshing mind, relieving sore throat, promoting eruption, dispersing stagnated liver qi, and promoting qi circulation. Can be used for treating wind-heat type common cold, headache, conjunctival congestion, pharyngitis, aphtha, rubella, measles, and chest and hypochondrium swelling. Mint is light in weight, fragrant and floating, and has the effects of dredging orifices, dispelling wind-heat from upper jiao, refreshing head and eyes, and relieving sore throat, so it can be used for treating headache, vertigo, conjunctival congestion, lacrimation, sore throat, and aphtha of mouth and tongue caused by wind-heat attacking upwards. Mint enters liver meridian and can soothe liver and promote qi circulation; therefore, it can be used for treating liver qi stagnation (pharmacopoeia of the people's republic of China, clinical medication need, volume of decoction of Chinese medicinal herbs, 120P 2015 edition).
The Glycyrrhrizae radix is dried root and rhizome of Glycyrrhiza uralensis Fisch, Glycyrrhiza inflata Bat, or Glycyrrhiza glabra L. Licorice root, radix Glycyrrhizae is sweet in nature and taste, and mild in nature and flavor. It enters heart, lung, spleen and stomach meridians. Has the effects of invigorating spleen and replenishing qi, clearing away heat and toxic materials, eliminating phlegm and relieving cough, relieving spasm and pain, and harmonizing the medicines. Can be used for treating weakness of spleen and stomach, asthenia, palpitation, short breath, cough, excessive phlegm, abdominal and limb spasm, pain, carbuncle, swelling, sore, and drug toxicity and strong nature. The liquorice is sweet in taste and neutral in nature and enters heart, lung, spleen and stomach meridians; it is good at tonifying heart qi, promoting blood circulation, and restoring pulse, and can be used for treating heart qi deficiency, palpitation, and intermittent pulse; licorice root, radix Glycyrrhizae is sweet in flavor and slightly cold in nature, can clear away heat and toxic materials, and is commonly used for treating sore throat, carbuncle, swelling, sore and other diseases. Licorice root also has the action of moderating the property of herbs and harmonizing the herbs. Besides relieving the toxicity of the medicine, it can also be used for regulating the bias of cold and heat, the severity and the taste of the medicine (pharmacopoeia of the people's republic of China, clinical medication need know, Chinese medicine decoction pieces roll, 1105P of 2015 edition).
The Margarita is prepared from bivalve animals such as Pteria martensii (Dunker), Hyriopsis cumingii (Lea), or Cristaria plicata (Leach). Pearl is sweet, salty and cold in nature and taste. It enters heart and liver meridians. Has the functions of calming the nerves, arresting convulsion, improving eyesight, removing nebula, detoxifying, promoting granulation, moistening skin and removing speckles. Can be used for treating pavor, insomnia, infantile convulsion, epilepsy, conjunctival congestion, nebula, unhealing sore and ulcer, and skin mottle. Pearl is salty and cold, heavy and heavy in nature, enters heart and liver meridians, and can be used for tranquilizing mind and arresting convulsion, and is mainly indicated for unsteadiness of heart-mind, palpitation and insomnia. Because of its cold nature, clearing heat, sweet and cold property, benefiting yin, it is indicated for restlessness, insomnia, dreaminess, amnesia, restlessness due to heart yin deficiency with heat. Pearl has the effects of clearing liver heat, improving eyesight and removing nebula when entering liver channel, so it can be used for treating various eye diseases such as conjunctival congestion, pain and nebula generation caused by wind heat in liver channel or liver fire (pharmacopoeia of the people's republic of China, clinical medication need, Chinese medicinal tablet roll, version 1040P of 2015). It is also documented that amino acid components, trace calcium and other trace elements in pearl powder are effective components for exerting medicinal effects. Under the condition of over-high temperature, amino acid can be denatured, so that pearl powder should be added under the condition of cooling the medicine in the preparation process.
The pearl powder has the effects of improving eyesight, removing nebula, clearing heat and relieving spasm. According to the modern pharmacological research of traditional Chinese medicines, the nacreous layer powder hydrolysate contains various amino acids and various trace elements, including 8 amino acids necessary for human body, has the capability of protecting water-soluble protein (SOD) and reduced Glutathione (GSH) in rat crystalline lens, can inhibit lipid peroxidation and remove active oxygen free radicals, and has the effect of preventing cataract.
Borneol, this product is borneol synthesized by processing turpentine, camphor and other raw materials. Borneol is pungent, bitter and slightly cold in property. It enters heart, spleen and lung meridians. Has effects in inducing resuscitation, refreshing mind, clearing away heat, and relieving pain. Can be used for treating fever unconsciousness, convulsion, apoplexy with phlegm syncope, qi stagnation and sudden syncope, central nausea and coma, thoracic obstruction, cardialgia, conjunctival congestion, aphtha, sore throat, and purulence in ear canal. Borneol has pungent and fragrant smell and has the efficacy of inducing resuscitation and refreshing mind, and the borneol has the similar function as musk and has slower efficacy. It is cool and cold in nature, and is suitable for treating block fever and coma; borneol is pungent and fragrant, and its fragrant smell can be used as a long herb to relieve pain. Borneol is bitter and cold in property, and has the functions of clearing heat and relieving pain, improving eyesight and removing nebula, promoting granulation and healing sore when being externally used (pharmacopoeia of the people's republic of China, clinical medication need know, volume of Chinese medicinal tablets, 1067P 2015 edition).
Menthol is composed of saturated cyclic alcohol obtained from oleum Menthae Dementholatum, and has effects of dispelling pathogenic wind, clearing away heat and toxic materials. The traditional Chinese medicine composition is mainly used for treating headache, conjunctival congestion and wind-heat common cold in clinic. When topically applied, it has effects of promoting blood circulation, relieving inflammation and itching, and can be used for relieving inflammation, itching, pain, and edema.
The invention has the advantages that:
the invention provides a pharmaceutical composition for preventing and treating myopia and asthenopia, which is prepared from the following components according to the concept of the invention into oral medicament and external medicament respectively, and the components of the formula have the effects of promoting blood circulation by removing blood stasis, improving blood circulation, maintaining eye nutrition, nourishing yin and kidney, clearing liver and improving vision, resisting fatigue and resisting oxidation. The medicine has the effects of dredging qi and blood, nourishing liver and kidney, nourishing blood, soothing nerves, promoting blood flow, improving blood circulation, regulating and controlling channels and collaterals, and improving eye muscle function, thereby realizing the treatment effect on myopia and asthenopia.
The pharmaceutical composition is added with pharmaceutically acceptable auxiliary materials to prepare an oral preparation, which undoubtedly brings more medication convenience for patients with myopia and asthenopia and is convenient to carry and take.
The pharmaceutical composition is added with proper auxiliary materials to prepare an external preparation, has more choices for the application of preventing and treating myopia and asthenopia, and achieves the ideal effect of treating the myopia and the asthenopia by utilizing the blood flow distribution of the capillary vessels in the eyes and the absorption and distribution of the capillary vessels around the eyes through the skin around the eyes.
Clinical tests prove that the oral preparation and the external preparation have obvious rehabilitation effect, short period, high cure rate and definite curative effect when being used for treating myopia or asthenopia; the use and return visit of patients prove that the product is safe to use, has no toxic or side effect, has no adverse reaction and has no treatment risk. The oral or external preparation has wide applicable population, and the product is satisfied after being treated and feels refreshing after being used for 8 years of age and 66 years of age at the minimum; the product of the invention is easy to be taken orally or externally, is easy to be popularized and popularized, and can benefit more myopes, especially asthenopia patients.
Detailed Description
Example 1
Preparation of the pharmaceutical composition:
prescription: 10 parts of safflower, 10 parts of salvia miltiorrhiza, 8 parts of ligusticum wallichii, 15 parts of white chrysanthemum, 10 parts of honeysuckle, 10 parts of coptis chinensis, 12 parts of green tangerine peel, 12 parts of mulberry leaves, 20 parts of phellinus igniarius, 20 parts of lucid ganoderma, 10 parts of wolfberry, 20 parts of semen cuscutae, 8 parts of ginseng, 20 parts of astragalus membranaceus, 10 parts of semen plantaginis, 12 parts of semen cassiae, 10 parts of concha haliotidis, 10 parts of spina date seeds, 12 parts of caltrops, 9 parts of oysters, 12 parts of cicada slough, 8 parts of spirulina, 10 parts of sea-buckthorn, 8 parts of ginger, 20 parts of human placenta, 6 parts of mint, 9 parts of liquorice;
the preparation method comprises the following steps:
(1) respectively cleaning Saviae Miltiorrhizae radix, rhizoma Ligustici Chuanxiong, Coptidis rhizoma, pericarpium Citri Reticulatae viride, folium Mori, Phellinus Linteus, Ganoderma, fructus Lycii, semen Cuscutae, radix astragali, semen plantaginis, semen Cassiae, Concha Haliotidis, semen Ziziphi Spinosae, fructus Tribuli, Concha Ostreae, periostracum Cicadae, Spirulina, fructus Hippophae, rhizoma Zingiberis recens, and Glycyrrhrizae radix, microwave drying, and pulverizing into 40-50 mesh powder;
(2) mixing the medicinal powder obtained in step (1), moistening with edible ethanol for 40-50 hr, and adding edible ethanol at a dose of 0.3-1.5ml/kg-1Collecting percolate at flow rate of (medicinal materials weight), stopping percolating until the percolate turns light yellow, recovering ethanol from percolate, filtering, heating and concentrating to relative density of 1.75-2.25 (50 deg.C), to obtain concentrated solution I; adding purified water 8-10 times of the weight of the medicinal materials into the percolate, decocting with strong fire for 2 hr, decocting with slow fire for 1 hr, filtering to obtain decoction, concentrating the decoction to relative density of 1.72-2.25 (50 deg.C), and collecting concentrated solution II;
(3) cleaning Carthami flos, flos Chrysanthemi, flos Lonicerae, Ginseng radix, and herba Menthae, respectively, microwave drying, grinding into 40-50 mesh powder, mixing the powders, adding edible ethanol, soaking at room temperature for 5-7 days, wherein the amount of ethanol is 5-10 times of the weight of the medicinal materials, and the soaking time is 5-7 days, mixing the three soaking solutions, recovering ethanol, filtering, and concentrating to relative density of 1.15-1.25(50 deg.C) to obtain concentrated solution III; adding purified water 5 times the weight of the medicinal materials into the soaked medicine residues, heating and decocting for 2 hours, taking the decoction, filtering, and concentrating until the relative density is 1.15-1.25(50 ℃), so as to obtain a concentrated solution IV for later use;
(4) microwave drying placenta hominis, grinding into 50 mesh powder, adding 10 times, 8 times and 5 times of normal saline, boiling and extracting for three times, wherein the boiling time is 1 hour each time, mixing the decoctions, filtering, adjusting pH of the filtrate to 3.1-3.2 with 0.1mol hydrochloric acid, standing in a refrigerator for 24-36 hours, precipitating completely, collecting supernatant, filtering, heating and concentrating the filtrate to relative density of 1.05-1.12 (50 deg.C), and collecting concentrated solution V;
(5) mixing the concentrated solutions I, II, III, IV and V obtained in the steps (2), (3) and (4), adding soluble pearl powder in parts by weight, fully and uniformly mixing to obtain a mixed concentrated solution, performing vacuum drying on the mixed concentrated solution at a low temperature of 45-50 ℃ until the water content is less than 5%, cooling, and crushing to obtain the pharmaceutical composition.
(II) preparation of capsules:
mixing the medicinal composition with beta-cyclodextrin according to the weight ratio of 1:0.5, fully and uniformly grinding, sieving with a 150-mesh sieve, sterilizing, and filling 1.5g of the medicinal composition into a No. 00 capsule to obtain the capsule.
When the capsule for preventing and treating the myopia and the asthenopia of the eyes is used for preventing and treating the asthenopia of the eyes or slight myopia, the dosage is 2 times a day, 1 capsule is taken each time, the capsule is taken 1 time after breakfast and supper, and 30 days are a course of treatment.
The preparation is administered 3 times a day, 2 granules each time, 1 time after breakfast, lunch and supper, and 30 days is a treatment course.
For treating eye asthenopia, 2 times daily, 2 granules each time, 1 time after breakfast and supper, and 7 days as a treatment course.
The capsule of the invention is tried out and treated 126 cases of mild myopia, the response rate is 98%, the cure rate is 86%; for 196 cases of moderate myopia, the effective rate is 92 percent, and the cure rate is 76 percent; the medicine can treat and relieve 320 cases of symptoms such as asthenopia, eye pain, dryness, blurred vision, eye foreign body sensation, eyelid heaviness, photophobia and lacrimation, and has an effective rate of 100% and a cure rate of 96%.
Typical cases are:
case 1: the programmer of a certain civil enterprise in Xuzhou city, 29 years old, faced with a computer every day for more than 9 hours, and worn 250-degree glasses with two eyes with slight myopia. Symptoms of dry eyes, dry eyes and painful eyes often appear, and the feeling is very tired.
The capsule prepared by the invention in the embodiment 1 is taken 3 times a day, 2 capsules each time, after breakfast, lunch and supper every day, the feeling effect is obvious after 10 days of medication, the symptoms such as eye pain, dry eyes, eye dryness and the like disappear, the mental state is relaxed, the capsule is continuously taken for 20 days, after one treatment course is finished, the dosage is adjusted downwards by 50 degrees by glasses, and the capsule is basically not required to be worn by glasses.
Case 2: xiaoya men and women, 12 years old, students in primary school of experiment in Xuzhou copper mountain area, with moderate myopia in both eyes, wear 400 degree glasses.
The capsule prepared by the invention in the embodiment 1 is taken 3 times a day, 1 capsule each time, and after breakfast and supper each day, the feeling is better after 10 days of administration, after 1 course of administration, the degree of the capsule is adjusted downwards by 50 degrees by glasses, the capsule is continuously used for 3 courses, and the glasses are not needed basically when people go to class.
Case 3: zhang Feng, male, 24 years old, a certain brand of mobile phone store in urban area, both eyes have 0.5, the previous treatment has been performed by laser surgery, but the vision rebounds after one year and returns to 0.5. after taking the capsule product prepared by the embodiment 1 of the invention, the capsule product is taken three times a day, 2 capsules are taken each time, the vision is recovered to 0.9 after 2 courses of treatment, the vision is recovered to 1.2 after the capsule product is continuously taken for 2 courses of treatment, and the capsule product is stopped for 1 year at present and has no rebound sign.
Case 4: wenxingchun, female, 42 years old, Xuzhou automobile trunk, vision of both eyes of 0.4, myopia lasts for 20 years, and there is no obvious effect when various medicines for treating myopia are used, the capsule product prepared by the invention in the embodiment 1 is taken three times a day, 2 capsules each time, in the morning, in the middle and at night, after 3 courses of treatment, the vision of both eyes reaches 0.8, and after 5 courses of treatment, the vision of both eyes reaches 1.0, and after one year of medicine withdrawal, the follow-up is carried out, and there is no rebound sign.
Case 5: the capsules prepared by the capsule product prepared by the invention in example 1 are taken three times a day, 2 capsules each time, according to the daily administration after breakfast, lunch and supper, and are relieved after treatment of one treatment course, and the binocular vision is 1.2 after three treatment courses. The return visit after 12 months has no rebound phenomenon.
Case 6: the capsule product prepared in the invention 1 is administrated to college students with naked eye vision of less than 0.3 for the left eye and less than 0.3 for the right eye of 19 years old for three times a day, 2 capsules are taken every time after breakfast, lunch and supper every day, the binocular vision is 0.6 after two treatment courses, the capsule product is continuously taken for three treatment courses, and the binocular vision is 1.1 after the treatment. After one year, the return visit is carried out without relapse.
Case 7: the capsule product prepared in the embodiment 1 of the invention is taken three times a day, 2 capsules each time, after breakfast, lunch and supper every day, after three treatment courses, the left-eye vision is 0.6, the right-eye vision is 0.8, the clinical symptoms are obviously improved, and the capsule is still in continuous treatment at present.
Case 8: yangxianzhen, female, a policeman in 29 years old, Xuzhou city, with a binocular vision of 1.4, due to the long-term use of computers, the eyes often feel dry, distending pain, blurred vision and other obvious asthenopia symptoms. The capsule product prepared in the embodiment 1 of the invention is taken 3 times a day, 2 capsules each time, 1 time after breakfast and supper each day, after 7 days of treatment in one treatment course, the symptoms are obviously relieved, after two treatment courses of continuous administration, the symptoms disappear, the patients feel refreshed, the eyes have no fatigue, and the patients return to visit after 6 months without rebound signs.
Case 9: heng ya Wei, male, 62 years old, and when a certain organ retires the cadres, the mobile phone always feels eye swelling, dry eyes, itching, eye socket pain and blurred vision for more than 6 hours each day. The capsule product prepared in the embodiment 1 of the invention is taken 2 times a day, 2 capsules each time, 1 time after breakfast and supper, the symptoms are obviously improved after 7 days of application for one treatment course, and the eye fatigue symptoms basically disappear after two treatment courses of continuous administration. The patient takes the medicine 1 granule every other week for 7 days, and takes the medicine once every morning and evening meal, the use time is up to 8 months, and symptoms such as eye swelling, dryness and eye pain do not appear during the administration period. The capsule product has better effect of preventing eyestrain.
In the revisiting of 126 cases of mild myopia treatment and 196 cases of moderate myopia and 320 cases of treating and relieving asthenopia, the capsule prepared by the invention has no toxic or side reaction such as allergy, gastrointestinal discomfort and the like, and patients all have normal reaction of diet, work and rest, normal regular urination and defecation and have no uncomfortable feeling. The survey and return visit information shows that the product of the invention has no big toxic and side effect and general adverse reaction. Can show that the product is safe and effective.
Example 2
Preparing a pharmaceutical composition:
prescription: 8 parts of safflower, 8 parts of salvia miltiorrhiza, 6 parts of ligusticum wallichii, 12 parts of white chrysanthemum, 8 parts of honeysuckle, 8 parts of coptis chinensis, 8 parts of green tangerine peel, 10 parts of mulberry leaves, 15 parts of phellinus igniarius, 15 parts of lucid ganoderma, 8 parts of wolfberry, 15 parts of semen cuscutae, 5 parts of ginseng, 15 parts of astragalus membranaceus, 5 parts of semen plantaginis, 5 parts of semen cassiae, 5 parts of concha haliotidis, 5 parts of spina date seeds, 8 parts of caltrops, 6 parts of oysters, 8 parts of cicada slough, 5 parts of spirulina, 5 parts of sea buckthorn, 6 parts of ginger, 12 parts of human placenta, 4 parts of mint, 6 parts of;
the preparation method comprises the following steps: the same as in example 1.
(II) preparation of tablets
Taking the pharmaceutical composition, adding starch, lactose and methyl cellulose, uniformly mixing, wetting by using 65% ethanol, preparing a soft material, granulating, drying, grading, mixing with magnesium stearate, and tabletting to obtain the tablet of the invention.
Example 3
Preparing a pharmaceutical composition:
prescription: 12 parts of safflower, 12 parts of salvia miltiorrhiza, 10 parts of ligusticum wallichii, 18 parts of white chrysanthemum, 12 parts of honeysuckle, 12 parts of coptis chinensis, 15 parts of green tangerine peel, 15 parts of mulberry leaves, 25 parts of phellinus igniarius, 25 parts of lucid ganoderma, 12 parts of wolfberry, 25 parts of semen cuscutae, 12 parts of ginseng, 30 parts of astragalus membranaceus, 15 parts of semen plantaginis, 15 parts of semen cassiae, 15 parts of concha haliotidis, 15 parts of spina date seeds, 16 parts of caltrops, 12 parts of oysters, 16 parts of cicada slough, 10 parts of spirulina, 15 parts of sea buckthorn, 12 parts of ginger, 25 parts of human placenta, 10 parts of mint, 12 parts of liquorice;
the preparation method comprises the following steps: the same as in example 1.
(II) preparation of granules:
taking the pharmaceutical composition, adding sucrose and dextrin, uniformly mixing, wetting by using ethanol with the concentration of 75% V/V, preparing a soft material, granulating, drying, grading, quantitatively packaging, and preparing the granule of the invention.
The invention also aims to provide an external preparation of the pharmaceutical composition for preventing and treating myopia and/or asthenopia, which can be prepared into solutions, powders, suspensions, ointments, plasters, creams, sprays and pastes, and is more preferably a paste. The material of the application agent is selected from non-woven fabric, the non-woven fabric is cut into a rectangle with the length of 18 cm and the width of 8 cm, the non-woven fabric is immersed into the prepared liquid medicine, the liquid medicine is taken out and drained after a certain time, and the liquid medicine is filled into a polypropylene or aluminum foil bag and sealed to obtain the adhesive. When in use, the non-woven fabric after being soaked is pasted on the periphery of eyes, and the non-woven fabric is selected to be pasted respectively in the morning and at the evening or in the morning, in the middle and at the evening according to different degrees of symptoms of myopia and asthenopia of patients, and the application time is 30-60 minutes each time.
The external preparation of the pharmaceutical composition for preventing myopia and/or asthenopia comprises the following specific embodiments:
example 1
Mixing 700g of polyethylene glycol 400 and 150g of propylene glycol uniformly, adding 50g of sodium carboxymethylcellulose, standing, soaking for 3 hours, stirring to dissolve uniformly, adding 100g of the pharmaceutical composition into the solution, stirring to dissolve, adjusting the pH value to 6.5-7.0, filtering to obtain a pharmaceutical composition liquid medicine, immersing the cut non-woven fabric into the liquid medicine for 8 hours, taking out the non-woven fabric soaked with the pharmaceutical composition, hanging and draining the flowing liquid medicine, filling into aluminum foil bags, sealing one sheet in each bag, packaging according to 100 bags per box after product packaging, and performing treatment on the pharmaceutical composition liquid medicine60Co radiation sterilization to obtain; the pharmaceutical composition described in this embodiment is prepared from the following raw materials in parts by weight:
10 parts of safflower, 10 parts of salvia miltiorrhiza, 6 parts of ligusticum wallichii, 15 parts of white chrysanthemum, 10 parts of honeysuckle, 10 parts of coptis chinensis, 12 parts of green tangerine peel, 12 parts of mulberry leaves, 20 parts of phellinus igniarius, 20 parts of lucid ganoderma, 10 parts of wolfberry, 20 parts of semen cuscutae, 8 parts of ginseng, 20 parts of astragalus membranaceus, 10 parts of semen plantaginis, 10 parts of semen cassiae, 10 parts of concha haliotidis, 10 parts of spina date seeds, 12 parts of caltrops, 9 parts of oysters, 12 parts of cicada slough, 8 parts of spirulina, 10 parts of sea-buckthorn, 8 parts of ginger, 20 parts of human placenta, 9 parts of liquorice, 6 parts of pearl powder, 6 parts of;
the preparation method comprises the following steps:
(1) respectively cleaning Carthami flos, Saviae Miltiorrhizae radix, rhizoma Ligustici Chuanxiong, flos Chrysanthemi, flos Lonicerae, Coptidis rhizoma, pericarpium Citri Reticulatae viride, folium Mori, Phellinus Linteus, Ganoderma, fructus Lycii, semen Cuscutae, Ginseng radix, radix astragali, semen plantaginis, semen Cassiae, Concha Haliotidis, semen Ziziphi Spinosae, fructus Tribuli, Concha Ostreae, periostracum Cicadae, Spirulina, fructus Hippophae, rhizoma Zingiberis recens, and Glycyrrhrizae radix, microwave drying, and pulverizing into 80 mesh powder; mixing the medicinal powder, and adding the medicinal powder into the mixture according to the weight ratio of 1: 10. 1: 7. 1: soaking 5V/V ethanol (30-65%) at 40-42 deg.C for three times (first 72 hr, second 48 hr, and third 24 hr) in ethanol, mixing the soaking solutions for 3 times, filtering, and recovering ethanol to obtain extractive solution;
(2) and (3) soaking the filter residue obtained in the step (1) for three times according to the weight of the medicinal materials of 1: adding purified water at a ratio of 15-20, decocting with strong fire for 3 hr, decocting with slow fire for 1 hr, filtering to obtain decoction, and concentrating to obtain concentrated solution with specific gravity of 1.15 (50 deg.C);
(3) microwave drying placenta hominis, pulverizing into 50 mesh powder, adding 10 times, 8 times and 5 times of normal saline, boiling and extracting for three times (each time for 1 hr), mixing the three decoctions, filtering, adjusting pH to 3.1-3.2 with 0.1mol hydrochloric acid, placing in refrigerator, standing at 1-2 deg.C for 24-36 hr, collecting supernatant after the solution is completely precipitated, and filtering to obtain filtrate;
(4) mixing the extract obtained in the step (1) and the concentrated solution obtained in the step (2) with the filtrate obtained in the step (3), concentrating by thin film evaporation to obtain a thick paste with the water content of 25 percent by weight, drying the thick paste in vacuum at 48-50 ℃, crushing and sieving to obtain 100-mesh powder;
(5) grinding borneol and menthol in parts by weight together, sieving the ground mixture with a 300-mesh sieve, mixing the ground mixture with water-soluble pearl powder in parts by weight, uniformly grinding the mixture, and adding the mixture into the 100-mesh powder obtained in the step (4) to be fully and uniformly blended to obtain the pharmaceutical composition.
Clinical trials prove that the application agent prepared in the embodiment can be used for treating and relieving symptoms such as eye pain, dryness, eye swelling and the like for 420 cases, the effective rate is 100%, and the cure rate is 90%. For 120 cases of pseudomyopia treatment, the effective rate is 95%, and the cure rate is 75%.
Typical cases are:
case 1
The patients: likeka, male, 30 years old
Symptoms are: when the user touches a computer for a long time, the user often feels pain, fullness and dryness of eyes.
The eye pain and dryness symptoms are relieved after the eye patch is applied to the periphery of the eyes, the eye patch is applied for 30 minutes in the morning and at the evening, and the eye patch is applied to the eyes for 2 days. The symptoms disappear after the patient uses the medicine for one course.
Case 2
The patients: zhang Feng, male, 16 years old, school student
Symptoms are: pseudomyopia, moderate myopia in both eyes, and 450-degree myopia glasses.
The patch is applied to eyes for 10 days for a treatment course, the feeling is better, the patch has obvious curative effect after being applied to the eyes for 2 treatment courses, and the glasses are adjusted by 150 degrees after being applied to the eyes for two treatment courses. Continuously consolidate 2 courses of treatment, if the user does not need to wear glasses in class.
Case 3
The patients: sing Hai Wei, male, 12 years old, school student
Symptoms are: pseudomyopia, which is not worn all the time, often causes dry eyes and malaise eyes, and frequently blinks habitually.
The patch is applied to the periphery of eyes once a day in the morning and at night, each time is 30 minutes, the phenomenon of dry eyes is obviously reduced after the patch is used for 5 days, and after one course of treatment of eye application, eyes do not feel dry and get rid of the bad habit of frequent eye blinking. Then, the eye is applied once a day at night, and the consolidation treatment is carried out for 30 minutes each time. Half a year later, the symptoms disappear completely.
Case 4
Patient, Zhang Xiaoxia, girl, 16 years old, student at school
Symptoms are: pseudomyopia, moderate myopia in both eyes, and wearing 400-degree myopia glasses.
The patch is applied to eyes once in the morning and at night, each time is 30 minutes, after five days, the feeling is better, after two courses of eye application, the glasses are lowered by 50 degrees, the glasses are continuously used for 3 courses, and the glasses are basically not needed to be worn in class.
Case 5
Patient, Du Xiao Yang, male, 12 years old, student at school
Symptoms are: pseudomyopia, mild myopia in both eyes, left eye < 0.6, right eye < 0.8, no glasses, but dry eye, eye puckery, eye pain, and very tired feeling.
The patch is applied to the periphery of eyes once in the morning and at night every day, each time is 30 minutes, symptoms are relieved after continuous use for 5 days, the patch has relaxed feeling, the application symptoms disappear after three treatment courses of insistence, and the eyes are corrected for vision by two eyes by 1.2. The disease does not relapse after one-year return visit.
Case 6
The patients: the people of the folk nationality, women, age 32 and white collar, face the computer for more than 8 hours every day, and often feel dry and astringent eyes, eye pain, lacrimation and sour and swollen eyes.
The application agent is applied to the periphery of eyes once a day in the morning and at night, so that the dry eye symptom is obviously improved after one treatment course, the periphery of the eyes gradually generates heat, and the blood circulation is promoted. The three courses of treatment are insisted on, the previous symptoms are basically improved, and the eyestrain is obviously improved.
Case 7
The patients: shangbeiyun, male, age 68, electrician professional retirement.
Symptoms are: the old people can watch the mobile phone all day and the eyesight of the old people is rapidly reduced, the eyes are sore and painful, the old people often tear and cannot see things clearly in recent years.
After the patch is applied to the periphery of eyes for 10 days, the situation of tearing of the eyes is obviously improved, the eyes are not dry and astringent, and the symptoms of ache are obviously relieved. After the patient returns visit after being stopped for 6 months, the patient can self-tell that the symptoms of dry eyes and ache disappear, and the eyes do not lacrimate.
It should be noted that: the above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and it is obvious to those skilled in the art that modifications and partial replacement of technical features of the present invention may be made in the foregoing embodiments. Any modification, modification or substitution made within the basic principle of the present invention should be considered as the protection scope of the present invention.
Claims (13)
1. A pharmaceutical composition for preventing and treating myopia and/or asthenopia is characterized by being prepared from the following raw materials in parts by weight: 8-12 parts of safflower, 8-12 parts of salvia miltiorrhiza, 6-10 parts of ligusticum wallichii, 12-18 parts of white chrysanthemum, 8-12 parts of honeysuckle, 8-12 parts of coptis chinensis, 8-15 parts of green tangerine orange peel, 10-15 parts of mulberry leaves, 15-25 parts of phellinus igniarius, 15-25 parts of lucid ganoderma, 8-12 parts of wolfberry fruit, 15-25 parts of semen cuscutae, 5-12 parts of ginseng, 15-30 parts of astragalus membranaceus, 5-15 parts of semen plantaginis, 5-15 parts of semen cassiae, 5-15 parts of concha haliotidis, 5-15 parts of spina date seeds, 8-16 parts of caltrops, 6-12 parts of oysters, 8-16 parts of periostracum cicada, 5-10 parts of spirulina, 5-15 parts of sea buckthorn, 6-12 parts of ginger, 12-25 parts of placenta hominis, 4-10 parts of mint, 6-12 parts of.
2. The pharmaceutical composition for preventing and treating myopia and/or asthenopia according to claim 1, which is prepared from the following raw materials in parts by weight: 10 parts of safflower, 10 parts of salvia miltiorrhiza, 8 parts of ligusticum wallichii, 15 parts of white chrysanthemum, 10 parts of honeysuckle, 10 parts of coptis chinensis, 12 parts of green tangerine peel, 12 parts of mulberry leaves, 20 parts of phellinus igniarius, 20 parts of lucid ganoderma, 10 parts of wolfberry, 20 parts of semen cuscutae, 8 parts of ginseng, 20 parts of astragalus membranaceus, 10 parts of semen plantaginis, 12 parts of semen cassiae, 10 parts of concha haliotidis, 10 parts of spina date seeds, 12 parts of caltrops, 9 parts of oysters, 12 parts of cicada slough, 8 parts of spirulina, 10 parts of sea-buckthorn, 8 parts of ginger, 20 parts of human placenta, 6 parts of mint, 9 parts of liquorice.
3. The method for preparing a pharmaceutical composition for the prevention and treatment of myopia and/or ocular fatigue according to claim 1 or 2, characterized by comprising the steps of:
(1) respectively cleaning Saviae Miltiorrhizae radix, rhizoma Ligustici Chuanxiong, Coptidis rhizoma, pericarpium Citri Reticulatae viride, folium Mori, Phellinus Linteus, Ganoderma, fructus Lycii, semen Cuscutae, radix astragali, semen plantaginis, semen Cassiae, Concha Haliotidis, semen Ziziphi Spinosae, fructus Tribuli, Concha Ostreae, periostracum Cicadae, Spirulina, fructus Hippophae, rhizoma Zingiberis recens, and Glycyrrhrizae radix, microwave drying, and pulverizing into 40-50 mesh powder;
(2) mixing the medicinal powder obtained in step (1), moistening with edible ethanol for 40-50 hr, and adding edible ethanol at a dose of 0.3-1.5ml/kg-1Collecting percolate until the percolate turns light yellow, recovering ethanol from the percolate, filtering, heating and concentrating to relative density of 1.75-2.25/50 deg.C to obtain concentrated solution I; adding purified water 8-10 times of the weight of the medicinal materials into the percolate, decocting with strong fire for 2 hours, then decocting with slow fire for 1 hour, filtering to obtain decoction, and concentrating the decoction to relative density of 1.72-2.25/50 deg.C to obtain concentrated solution II;
(3) cleaning Carthami flos, flos Chrysanthemi, flos Lonicerae, Ginseng radix, and herba Menthae, respectively, microwave drying, grinding into 40-50 mesh powder, mixing the powders, adding edible ethanol, soaking at room temperature for three times, wherein the amount of ethanol is 5-10 times of the weight of the medicinal materials, the soaking time is 5-7 days, mixing the three soaking solutions, recovering ethanol, filtering, and concentrating to relative density of 1.15-1.25/50 deg.C to obtain concentrated solution III; adding purified water 5 times the weight of the medicinal materials into the soaked medicine residues, heating and decocting for 2 hours, taking decoction, filtering, and concentrating until the relative density is 1.15-1.25/50 ℃ to obtain concentrated solution IV for later use;
(4) microwave drying placenta hominis, grinding into 50 mesh powder, adding 10 times, 8 times and 5 times of normal saline, boiling and extracting for three times, wherein the boiling time is 1 hour each time, mixing decoctions, filtering, adjusting pH of the filtrate to 3.1-3.2 with 0.1mol hydrochloric acid, standing in a refrigerator for 24-36 hours, precipitating completely, collecting supernatant, filtering, and heating and concentrating the filtrate to relative density of 1.05-1.12/50 deg.C to obtain concentrated solution V;
(5) mixing the concentrated solutions I, II, III, IV and V obtained in the steps (2), (3) and (4), adding soluble pearl powder in parts by weight, fully and uniformly mixing to obtain a mixed concentrated solution, drying the mixed concentrated solution at low temperature until the water content is less than 5%, cooling, and crushing to obtain the pharmaceutical composition.
4. The pharmaceutical composition for preventing and treating myopia and/or asthenopia according to claim 1 or 2, wherein the pharmaceutical composition is an oral preparation.
5. The pharmaceutical composition for preventing and treating myopia and/or asthenopia according to claim 4, wherein the oral preparation is oral liquid, syrup, tablet, capsule, granule, pill or paste.
6. The pharmaceutical composition for preventing and treating myopia and/or asthenopia according to claim 5, wherein the oral preparation is tablet or capsule.
7. A pharmaceutical composition for preventing and treating myopia and/or asthenopia is characterized by being prepared from the following raw materials in parts by weight: 8-12 parts of safflower, 8-12 parts of salvia miltiorrhiza, 6-10 parts of ligusticum wallichii, 12-18 parts of white chrysanthemum, 8-12 parts of honeysuckle, 8-12 parts of coptis chinensis, 8-15 parts of green tangerine orange peel, 10-15 parts of mulberry leaves, 15-25 parts of phellinus igniarius, 15-25 parts of lucid ganoderma, 8-12 parts of wolfberry fruit, 15-25 parts of semen cuscutae, 5-12 parts of ginseng, 15-30 parts of astragalus membranaceus, 5-15 parts of semen plantaginis, 5-15 parts of semen cassiae, 5-15 parts of concha haliotidis, 5-15 parts of spina date seeds, 8-16 parts of caltrops, 6-12 parts of oysters, 8-16 parts of periostracum cicada, 5-10 parts of spirulina, 5-15 parts of sea buckthorn, 6-12 parts of ginger, 12-25 parts of placenta hominis, 6-12 parts of liquorice, 4-8 parts of, 4-8 parts of menthol.
8. The pharmaceutical composition for preventing and treating myopia and/or asthenopia according to claim 7, which is prepared from the following raw materials in parts by weight: 10 parts of safflower, 10 parts of salvia miltiorrhiza, 6 parts of ligusticum wallichii, 15 parts of white chrysanthemum, 10 parts of honeysuckle, 10 parts of coptis chinensis, 12 parts of green tangerine peel, 12 parts of mulberry leaves, 20 parts of phellinus igniarius, 20 parts of lucid ganoderma, 10 parts of wolfberry, 20 parts of semen cuscutae, 8 parts of ginseng, 20 parts of astragalus membranaceus, 10 parts of semen plantaginis, 10 parts of semen cassiae, 10 parts of concha haliotidis, 10 parts of spina date seeds, 12 parts of caltrops, 9 parts of oysters, 12 parts of cicada slough, 8 parts of spirulina, 10 parts of sea-buckthorn, 8 parts of ginger, 20 parts of human placenta, 9 parts of liquorice, 6 parts of pearl powder, 6 parts of.
9. The method for preparing a pharmaceutical composition for the prevention and treatment of myopia and/or asthenopia according to claim 7 or 8, which comprises the steps of:
(1) respectively cleaning Carthami flos, Saviae Miltiorrhizae radix, rhizoma Ligustici Chuanxiong, flos Chrysanthemi, flos Lonicerae, Coptidis rhizoma, pericarpium Citri Reticulatae viride, folium Mori, Phellinus Linteus, Ganoderma, fructus Lycii, semen Cuscutae, Ginseng radix, radix astragali, semen plantaginis, semen Cassiae, Concha Haliotidis, semen Ziziphi Spinosae, fructus Tribuli, Concha Ostreae, periostracum Cicadae, Spirulina, fructus Hippophae, rhizoma Zingiberis recens, and Glycyrrhrizae radix, microwave drying, and pulverizing into 80 mesh powder; mixing the medicinal powder, and adding the medicinal powder into the mixture according to the weight ratio of 1: 10. 1: 7. 1: soaking 5V/V ethanol (30-65%) at 40-42 deg.C for three times (first 72 hr, second 48 hr, and third 24 hr) in ethanol, mixing the soaking solutions for 3 times, filtering, and recovering ethanol to obtain extractive solution;
(2) and (3) soaking the filter residue obtained in the step (1) for three times according to the weight of the medicinal materials of 1: adding purified water at a ratio of 15-20, decocting with strong fire for 3 hr, decocting with slow fire for 1 hr, filtering to obtain decoction, and concentrating to obtain concentrated solution with specific gravity of 1.15/50 deg.C;
(3) microwave drying placenta hominis, pulverizing into 50 mesh powder, adding 10 times, 8 times and 5 times of normal saline, boiling and extracting for three times (each time for 1 hr), mixing the three decoctions, filtering, adjusting pH to 3.1-3.2 with 0.1mol hydrochloric acid, placing in refrigerator, standing at 1-2 deg.C for 24-36 hr, collecting supernatant after the solution is completely precipitated, and filtering to obtain filtrate;
(4) mixing the extract obtained in the step (1) and the concentrated solution obtained in the step (2) with the filtrate obtained in the step (3), concentrating by thin film evaporation to obtain a thick paste with the water content of 25 percent by weight, drying the thick paste in vacuum at 48-50 ℃, crushing and sieving to obtain 100-mesh powder;
(5) grinding borneol and menthol in parts by weight together, sieving the ground mixture with a 300-mesh sieve, mixing the ground mixture with water-soluble pearl powder in parts by weight, uniformly grinding the mixture, and adding the mixture into the 100-mesh powder obtained in the step (4) to be fully and uniformly blended to obtain the pharmaceutical composition.
10. The pharmaceutical composition for preventing and treating myopia and/or asthenopia according to claim 7 or 8, which is an external preparation.
11. The pharmaceutical composition for the prevention and treatment of myopia and/or asthenopia according to claim 10, wherein the external preparation is a solution, powder, suspension, ointment, plaster, cream, patch or spray.
12. The pharmaceutical composition for the prevention and treatment of myopia and/or asthenopia according to claim 11, wherein the external preparation is an ointment, a patch or a spray.
13. The pharmaceutical composition for the prevention and treatment of myopia and/or asthenopia according to claim 12, wherein the external preparation is a patch.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011494953.XA CN112451649A (en) | 2020-12-17 | 2020-12-17 | Pharmaceutical composition for preventing and treating myopia and/or asthenopia and preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011494953.XA CN112451649A (en) | 2020-12-17 | 2020-12-17 | Pharmaceutical composition for preventing and treating myopia and/or asthenopia and preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112451649A true CN112451649A (en) | 2021-03-09 |
Family
ID=74802894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011494953.XA Pending CN112451649A (en) | 2020-12-17 | 2020-12-17 | Pharmaceutical composition for preventing and treating myopia and/or asthenopia and preparation thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112451649A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101433639A (en) * | 2007-11-16 | 2009-05-20 | 北京因科瑞斯医药科技有限公司 | Composition with function for alleviating eyestrain and preparation method thereof |
CN102657739A (en) * | 2012-05-29 | 2012-09-12 | 翟佳滨 | Eyesight adjusting ointment for myopia |
CN107334879A (en) * | 2017-06-01 | 2017-11-10 | 徐珂 | A kind of nano traditional Chinese medicine eye ointment for treating myopia and preparation method thereof |
CN109700889A (en) * | 2019-03-05 | 2019-05-03 | 朱月新 | A kind of Chinese medicine composition and preparation method thereof of health care eyes |
-
2020
- 2020-12-17 CN CN202011494953.XA patent/CN112451649A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101433639A (en) * | 2007-11-16 | 2009-05-20 | 北京因科瑞斯医药科技有限公司 | Composition with function for alleviating eyestrain and preparation method thereof |
CN102657739A (en) * | 2012-05-29 | 2012-09-12 | 翟佳滨 | Eyesight adjusting ointment for myopia |
CN107334879A (en) * | 2017-06-01 | 2017-11-10 | 徐珂 | A kind of nano traditional Chinese medicine eye ointment for treating myopia and preparation method thereof |
CN109700889A (en) * | 2019-03-05 | 2019-05-03 | 朱月新 | A kind of Chinese medicine composition and preparation method thereof of health care eyes |
Non-Patent Citations (2)
Title |
---|
徐建玲: "综合治疗中小学生近视的疗效观察", 《内蒙古中医药》 * |
李加木: "《营养平衡决定健康》", 30 September 2008 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520621B (en) | A kind of Chinese medicine composition for the treatment of senile cataract and preparation method thereof | |
CN104352887A (en) | Anti-tumor comprehensive conditioning cream and preparing technology thereof | |
CN104586669A (en) | Fat-reducing externally-applied cream | |
CN104740541A (en) | Health-care traditional Chinese medicine powder for protecting liver, detoxifying and recovering liver functions | |
CN1907064A (en) | Longevity health care tea | |
CN105663656A (en) | Pharmaceutical composition for treating sleep disorders and preparing method thereof | |
CN103977206B (en) | Improve Chinese medicine preparation and the production method thereof of gastrointestinal disturbances systemic-function | |
CN103550721B (en) | There is the Chinese medicine composition of the sleeping effect of blood pressure lowering and the medicated pillow containing said composition | |
CN102793848B (en) | Traditional Chinese medicine powder for treating night blindness | |
CN101485786B (en) | Whitening spot-eliminating composition and method for preparing the same | |
CN106215118A (en) | Antineoplastic health preparation and preparation method thereof | |
CN103393825B (en) | Traditional Chinese medicine for treating catatonic headache and preparation method thereof | |
CN104623600A (en) | Traditional Chinese medicine for treating peripheral neuritis and preparation method thereof | |
CN112451649A (en) | Pharmaceutical composition for preventing and treating myopia and/or asthenopia and preparation thereof | |
CN102451250A (en) | Chinese medicine footbath prescription for treating color spots | |
CN112245550A (en) | A Chinese medicinal composition with effect in regulating emotion, and its preparation method | |
CN112823807A (en) | Donkey-hide gelatin ginseng cream and preparation method thereof | |
CN104800610A (en) | Traditional Chinese medicine preparation for treating Parkinson's disease and preparation method thereof | |
CN101049371A (en) | Chinese medicament for treating barrenness without sperm, and preparation method | |
CN105497575A (en) | Traditional Chinese medicinal preparation for treating dysthymia | |
CN114712470B (en) | Medicine for treating deficiency of kidney of men and preparation method thereof | |
CN104606565B (en) | The Chinese medicinal capsule of Prevention and Curation ocular disease | |
CN112370523A (en) | A pharmaceutical composition and paste for preventing and treating asthenopia and myopia | |
CN104435651A (en) | Traditional Chinese medicine for protecting eyes and relieving visual fatigue | |
CN115590936A (en) | Health-care medicinal liquor and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |